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Abstract
Doxorubicin (DOX) blocks the autophagic flux in cardiomyocytes by inhibiting
lysosome acidification. The acidic pH of lysosomes is maintained by the V-ATPase pump.
NAD+ is an essential cofactor for the maintenance of cellular homeostasis. DOX treatment
significantly depletes the NAD+ levels in cardiomyocytes. This study investigated the
potential of the NAD+ precursor, nicotinamide mononucleotide (NMN), in preventing DOXinduced cardiotoxicity. DOX induced cell injury and altered the lysosomal pH of H9c2 cells,
an in vitro model of cardiomyocytes. These effects of DOX were attenuated by NMN. The
protection conferred by NMN was offset by inhibition of V-ATPase activity with bafilomycin
A. Furthermore, NMN prevented the DOX induced hyperacetylation of the V-ATPase
subunit ATP6V0d1, a critical protein involved in the maintenance of V-ATPase activity. In
summary, NMN protects cardiomyocytes from DOX induced toxicity by maintaining the pH
of lysosomes. Thus, NMN holds potential in combating the deleterious impacts of
Doxorubicin on the heart.
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ii

Summary for Lay Audience
Cancer is one of the leading causes of death worldwide. Nearly 1 in 2 Canadians
develop cancer during their lifetime. The harsh reality of cancer does not end with its onset.
The devastating dark side of the available treatment options like chemotherapy impacts the
patient’s quality of life. Doxorubicin, the chemotherapy antibiotic, is routinely used for the
treatment of multiple cancers. Its deadliest side effect is heart injury, which leads to heart
failure. In fact, over 50% of the childhood cancer survivors develop heart disease in the later
stages of their life. Doxorubicin impairs a cellular process known as autophagy in heart cells.
Autophagy or cellular recycling is a self-eating process by which the damaged components in
the cells can be degraded and recycled. This recycling process occurs in designated recycling
centres or specialized compartments called lysosomes in the cell. Efficient functioning of
lysosomes is rendered by their acidic nature or low internal pH. This helps the lysosomal
proteins to break down the cellular debris. The low pH in lysosomes is achieved with the help
of a cellular pump called V-ATPase positioned on the lysosomal membrane. V-ATPase
transports protons into the lysosome and maintains optimal pH. Doxorubicin increases the pH
of lysosomes and it could most likely be by damaging the V-ATPase pump, but the exact
mechanism remains unknown.
NAD+ is a critical molecule in the body which is required for many essential
reactions in the cell. Doxorubicin decreases the natural levels of NAD+ in the body and
compromises the normal functioning of the cell. NAD+ depletion effects the lysosome
function too. This study aims to identify the impact of Doxorubicin treatment on the pH of
lysosomes and the V-ATPase pump in the heart cells. Nicotinamide mononucleotide (NMN)
is a vitamin B3 derivative and NAD+ supplement that provides many essential benefits to the
body. The role of NMN in preventing the harmful effects of Doxorubicin have been
investigated in this study. The results indicate that NMN has promising potential in protecting
the heart from the side effects of Doxorubicin.
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Chapter 1
1 Introduction
Cancer is the leading cause of death in Canada and the Canadian Cancer Society
estimates more than 80,000 deaths and 225,000 newly diagnosed cases in the country in
2020. Lung, breast, prostate and colorectal cancers together account for about nearly half of
the newly diagnosed cases in Canada. Though the incidence is higher in population aged
more than 50, it can affect at any age (1). Chemotherapy is most often used as the treatment
option alone or in combination with radiation, surgery etc. The word “chemotherapy” was
coined by the renowned German chemist Paul Ehrlich in the early 1900’s to address the use
of chemicals to treat disease. Nitrogen mustard was one of the earliest chemotherapy agents
used for cancer treatment. Even though the initial hype stirred considerable interest in the
drug, it soon subsided as remissions occurred in treated patients (2).
Cancer chemotherapy is a double-edged sword attacking both tumour cells and normal
cells alike. This could lead to deleterious side effects and so deciphering the mechanistic
action of these drugs in malignant and non-malignant cells is of high importance.
Doxorubicin is a commonly administered chemotherapy agent worldwide and it is used in
adult and paediatric cancer patients alike with commendable recovery rates. Due to its
toxicity profile and bright red appearance, Doxorubicin has been notoriously nicknamed as
the “Red Devil”. Alongside the common side effects of most chemotherapeutic antibiotics,
like nausea, vomiting, mouth sores and alopecia, Doxorubicin could elicit irreversible
damage to the heart as well. Though widely studied, the mechanisms of Doxorubicin
triggered cardiac injury remains elusive. Numerous drug candidates have entered clinical
trials to combat the side effects of Doxorubicin, but none of them have been completely
successful so far (3). This study explores the mechanism and potential of Nicotinamide
mononucleotide, a vitamin B3 derivative of natural origin, in preventing the cardiotoxic side
effects of Doxorubicin in an in vitro model of disease.
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1.1 Anthracyclines
The efforts to investigate potential anti-neoplastic agents from soil microbes by the
Italian company, Farmitalia Research Laboratories, led to the discovery of the first
anthracycline antibiotic. Prof. Di Marco and his team isolated and purified a red pigment
from a spore forming Streptomyces peucetius found in the soil near the Castel del Monte on
the shores of the Adriatic Sea. This drug showed promising anti-tumor activity and was
named Daunomycin. A similar drug with identical physicochemical properties was isolated
by a French research group led by Maurice Dubost from Streptomyces coeruliorubidus at
about the same time and was named Rubidomycin. The name daunorubicin was hence
internationally adopted to avoid conflicts and by late 1960’s it was clinically introduced for
cancer treatment (4). The success of the new drug soon initiated the drive for development of
analogues with higher therapeutic index.
Chemical mutagenesis of Streptomyces peucetius led to the development of a variant
which produced another anthracycline antibiotic, Doxorubicin. Epirubicin and Idarubicin
were synthetically developed from Doxorubicin and Daunorubicin, respectively. Epirubicin
exerts lower cardiotoxic effects and Idarubicin is more lipophilic compared to their parent
drugs. Several new drugs were later added to this group and the list remains inexhaustive
(Table 1). Though anthracyclines showed promise in their efficacy for the treatment of
cancer, the toxic side effects mainly related to cardiac health were soon reported in patients,
raising concerns. Despite this, anthracycline therapy remains an important cancer treatment
regimen after nearly 50 decades of its discovery and is included in the World Health
Organization’s list of essential medicines. Daunorubicin, Doxorubicin, Epirubicin and
Idarubicin are the commonly used anthracyclines in the clinics at present (Figure 1.1) (5,6).
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Table 1: Anthracycline drugs
Anthracycline

Trade Name

Indications

Daunorubicin

Daunoxome, Cerubidine ®

acute lymphocytic leukemia

Doxorubicin

Doxil®, Rubex ®

Epirubicin

Ellence

Idarubicin

Idamycin

solid tumors, hematoligic
malignancies
axillary node metastases after
surgical breast cancer resection
acute myeloid leukemia

Valrubicin

Valstar, Valtaxin

bladder carcinoma

Aldoxorubicin

-

Under investigation

Annamycin

-

Under investigation

Plicamycin

Mithracin

testicular cancer

Sabarubicin

-

Under investigation

Zoptarelin doxorubicin

-

Under investigation

3

Figure 1.1: Chemical Structure of Anthracyclines. The four commonly used anthracycline
drugs Doxorubicin, Daunorubicin, Idarubicin and Epirubicin.
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1.2 Doxorubicin
Doxorubicin (DOX) is produced as a secondary metabolite from the bacterial strain
Streptomyces peucetius var. caesius. It was initially named Adriamycin, in recognition of the
Adriatic Sea, from where daunomycin, the first anti-cancer anthracycline was discovered (4).
DOX is extensively used in the treatment of solid tumors of the breast, lung, and bladder,
cervical cancer, lymphomas and sarcomas, in combination with other drugs such as
cyclophosphamide, paclitaxel etc. (7). Attributed to the efficiency of the drug in
chemotherapy treatment, the global DOX market is forecasted to be about 1.38 billion USD
by the year 2024, with North America contributing the major share followed by Europe and
Asia Pacific (8).
The chemical structure of DOX is comprised of a characteristic anthracycline
tetracyclic ring with an adjacent quinone-hydroquinone group linked to a sugar moiety,
daunosamine, by a glycosidic bond. The presence of a methoxy group attached to the
tetracyclic ring and methyl group attached to daunosamine distinguishes DOX from its
analogues (9). As the oral bioavailability of DOX is very low (< 1%) due to limited intestinal
absorption, it is intravenously administered and undergoes rapid tissue distribution and slow
elimination (10). DOX rapidly exits the circulation and accumulates in tissues, mostly in the
liver. It does not cross the blood-brain barrier despite being highly penetrative. The
metabolism of DOX begins in the liver and transforms to its main active immediate
metabolite Doxorubicinol in a NADPH dependent conversion by carbonyl reducing enzymes.
The sugar components of DOX and Doxorubicinol undergoes acid catalysed hydrolysis to
form the aglycones, doxorubicinone and doxorubicinolone, respectively. These metabolites
are then excreted in urine and faeces (11).
More than 2000 analogues of DOX have been synthesized and have been researched
for their anti-neoplastic potential. Efforts to develop more efficient and less toxic analogues
led to the use of liposomal encapsulation technology. Doxorubicin was the first anti-cancer
drug to reach clinical trials as a lipid-based formulation. Liposomes are mostly confined to
the vascular system, and limits the exposure of doxorubicin to the myocardial cells having
tight junctions. Since the tumour cells are not tightly joined, the liposomal drug can exit the
circulation and accumulate in these cells. Phospholipids of the liposomes are derived from
natural sources like egg yolk and soya bean and can be eliminated from the circulation within
a few hours by plasma protein opsonization. But this short half-life limits its potential to a
5

certain extent. To overcome this, polymers such as polyethylene glycol (PEG), ganglioside,
and cerebroside sulphate that resisted opsonization were incorporated to the liposomal
formulation. Pegylated- liposomal DOX is now available under the trade name Doxil® and
has a circulatory half-life of 3-4 days. Adding a PEG molecule however, because of its large
size, could limit the entry of liposome to the tumour cells and decrease the accumulation of
DOX. Also, since Doxil® has high affinity towards the skin, it causes a dose-limiting handfoot syndrome (HFS) in nearly 50% of patients treated with the drug. Non-pegylated versions
of liposomal encapsulated DOX such as Myocet® have been introduced into the North
American market but is relatively expensive (12).

1.2.1 Anti-cancer mechanism
The chemotherapeutic efficacy of DOX is attributed to its interaction with DNA,
topoisomerase inhibition and generation of reactive oxygen species (ROS) (13). It covalently
interacts with double stranded DNA by intercalating between the bases. At the maximum
saturation level, one molecule of DOX intercalates into every fifth base-pair of DNA. A
partial B to A-DNA transition occurs in the structure which accounts for the anti-cancer
activity of the drug (14). Topoisomerases are ubiquitous enzymes involved in the replication,
transcription, recombination, repair, and chromatin modelling. DOX inhibits topoisomerases
and disrupts the repair and replication mechanisms in the nucleus (15,16).
DOX also undergoes reduction to form a semiquinone radical by cellular oxidases,
which reacts with oxygen, generating ROS and exerts toxic effects on the cancer cells or gets
oxidised back by redox cycling (17). The drug interacts with the plasma proteins too and gets
reduced resulting in the formation of the highly potent hydroxyl radicals. Apoptosis is
triggered in cells when the repair process in response to DNA damage fails. DOX treatment
activates the p53 pathway and downregulates Bcl-2 expression subsequently activating the
effector caspases, the mediators of apoptosis (11).
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Figure 1.2: Anti-cancer mechanism of Doxorubicin. DOX exerts its anti-cancer properties
by intercalating into the DNA, inhibiting the topoisomerases and generating free radicals.

1.3 Doxorubicin Cardiotoxicity
The adverse effects of DOX and other anthracycline analogues on cardiac health were
reported by late 1960’s (18). But still, even after nearly 5 decades, it remains a key player in
the chemotherapeutic regime amidst the outcomes. Occurrence of cardiac complications is
estimated in one among eight DOX-treated patients (19). The cardiotoxic events associated
with DOX could be acute which occurs during or immediately after treatment, or chronic,
occurring within a year (early-onset) or several years post-treatment (late-onset). Acute DOX
cardiotoxicity is reversible, and manifestations could include reduced contractility,
pericarditis, myocarditis, sinus tachycardia, ST-T wave changes and decreased QRS complex
amplitude. Early-onset chronic complications include dilated cardiomyopathy with reduced
ejection fraction, electrical conduction changes, valve damage and reduced contractility.
7

Late-onset cardiotoxicity is often a silent killer, is irreversible and progresses to heart failure.
The progressive nature of chronic DOX cardiotoxicity places the cancer survivors receiving
the medication at immense risk and the prognosis remains poor (19–21).

1.3.1 Pathophysiology
Dilated cardiac chambers, reduced ventricular ejection fractions, diastolic
dysfunction, changes in the ventricular wall thickness are some of the pathological
occurrences associated with Doxorubicin treatment. Structural deformities such as
myocardial interstitial fibrosis, vacuolated cardiomyocytes, nuclear-chromatin
disorganization, distended sarcoplasmic reticulum, damaged mitochondria and increased
number of autophagic vacuoles are evident as well (20,22).

1.3.2 Risk Factors
Age, gender, cumulative dose, genetic predispositions, and pre-existing medical
history are all considered as risk factors leading to DOX induced cardiomyopathy. Nearly
48% of the patients receiving a cumulative dose of more than 700 mg/m2 of DOX end up
having congestive heart failure (20,21,23). More than 57% childhood cancer survivors have
been reported to develop chronic cardiac complications (24). Female gender is a further risk
factor in paediatric cancer patients while adult males are considered at more risk than their
counterparts (25). Individuals having variants of several genes have been associated with
increased risk of Anthracycline-induced toxicity as well (26). The epidemiology of DOX
induced cardiomyopathy stresses the importance of clinically relevant preventive treatment
strategies and hence research into elucidating the pathogenesis of DOX cardiotoxicity is
important and would lead to the identification of more molecular targets for drug
development (Figure 1.3).
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Figure 1.3: Risk factors associated with DOX-induced cardiomyopathy.
Incidence of DOX related toxicity and cardiomyopathy increases with age (children and
aged), gender, cumulative dose (>700 mg/m2), genetic make-up of the individual and preexisting health conditions.
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1.3.3 Mechanisms of Cardiotoxicity
Accumulation of DOX in the myocardium, coupled with the low levels of endogenous
antioxidants within the heart exponentiate the potent cardiotoxic effects of the drug. DOX
rapidly enters the cells by passive diffusion and accumulates in intracellular compartments.
The nuclear concentration of DOX is 50-fold more than in the cytoplasm and nearly 2% of
the cytosolic load is distributed among other organelles such as Golgi, lysosomes and
mitochondria (11). Multiple mechanisms have been identified in the emergence and
progression of DOX cardiotoxicity. Increased oxidative stress, disruption of calcium
homeostasis, apoptosis activation, DNA damage and autophagic dysregulation have been
implicated in the advancement of cardiac dysfunction (27).
DOX gets reduced to a semiquinone radical by cellular oxidases, Nitric oxide
synthase (NOS) and nicotinamide adenine dinucleotide phosphate-oxidase (NOX), which
then reacts with oxygen and generates free radicals. These radicals damage DNA and attack
the membrane lipids. DOX’s high affinity toward the cardiac-specific inner mitochondrial
membrane lipid, cardiolipin, disrupts the electron transport chain resulting in reduced ATP
production and increased mitochondrial ROS generation (28).
Cardiac muscle contractility is mediated by the excitation-contraction coupling in
cardiomyocytes regulated by the entry of calcium into the cytoplasm. The intracellular
calcium then induces the release of calcium from the sarcoplasmic reticulum (SR) by binding
to the ryanodine receptor. This process is termed as calcium-induced calcium release (CICR)
and it enables the contraction of cardiomyocytes. The uptake of calcium by the sarcoplasmic
reticulum calcium transport ATPase (SERCA) decreases the cytoplasmic calcium levels and
induces relaxation of cardiomyocytes. DOX-induces dysregulation of intracellular calcium
levels by several mechanisms. DOX binds to the ryanodine receptor and inhibits functioning.
It can also interact with luminal calcium binding proteins and the membranous SERCA pump
of the SR, and modify their actions resulting in impaired calcium handling and contribute to
the ROS pool (29).
The activation of the tumour suppressor p53 pathway by DOX stimulates apoptosis
and NF-κB activation induces inflammation and cytokine storm in cardiomyocytes (30).
DOX treatment also induced early stages of autophagy and suppressed the later stages
resulting in the inhibition of autophagic flux and accumulation of autophagosome generating
10

oxidative stress in cardiomyocytes (22). The role of ROS in the progressive decline of cardiac
health with DOX treatment has been well studied and documented (31). ROS mediated
disruptions in nuclear, lysosomal, mitochondrial, and endoplasmic reticulum events have an
evident role in the etiology of DOX cardiotoxicity (32). This study focusses on the role of
dysfunctional lysosomes in facilitating cardiomyocyte death.

Figure 1.4: Doxorubicin induces Cardiomyocyte cell death. DOX-induced ROS
generation coupled with low levels of antioxidants in the heart leads to oxidative stress and
effects the cardiomyocyte organelles.
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1.4 Autophagy and Cardiovascular diseases
Under normal physiological conditions, ROS generation from multiple sources
contribute to the induction of autophagy and the removal and recycling of damaged
organelles and defective proteins within the cell. The cellular debris is sequestered into a
double membraned vesicle, the autophagosome, in the endoplasmic reticulum. The loaded
autophagosome then fuses with the lysosome which subsequently leads to the degradation of
the debris by the lysosomal enzymes and is then released back into the cytosol (33).
The mammalian target of rapamycin complex 1 (mTORC1) and AMP-dependent
protein Kinases (AMPK) are the two signalling mechanisms implied in the control of
autophagy. mTORC1 signalling cascade is involved in numerous cellular processes
regulating growth, based on the nutritional and environmental intimations. Nutrient
starvation, cellular stress and certain growth factors negatively regulate mTORC1 and
promotes the induction of autophagy (34). Slight increases in the levels of AMP, can be
detected by AMPK which in turn phosphorylates many target proteins required for energy
homeostasis in the cell. AMPK mediated phosphorylation deactivates the mTORC1 complex,
thereby activating the autophagic machinery. AMPK also directly initiates autophagy via
mTORC1 independent pathways (35).
Both these signalling pathways are involved in the phosphorylation of the upstream
component of autophagy initiation, ULK1 (UNC 51 like kinase 1) kinase complex. mTORC1
binds to ULK1 complex rendering it inactive, while AMPK phosphorylates it and promotes
the downstream signalling (35–39). This serine/threonine kinase complex includes the
proteins ULK1, FIP200 (focal adhesion kinase family interacting protein of size 200 kDa),
ATG13 (autophagy related gene 13) and ATG101. The activated protein complex drives the
single membrane phagophore formation by activating the VPS34 (vacuole protein sorting 34)
complex comprised of class III phosphatidylinositol 3-kinase (PI3K), VPS34, VPS15
(vacuole protein sorting 15), BECLIN 1 and ATG14 (autophagy related gene 14) (40).
Interaction among the VPS34 complex components generates phosphatidylinositol 3phosphate (PI3P) promoting phagophore elongation and autophagosome formation. The
ATG5-ATG12-ATG16L complex dimer then associates with the evolving phagophore and
recruits lipidated LC3 (microtubule associated protein 1 light chain 3). Once the
autophagosome development is complete, the ATG5-ATG12-ATG16L complex dissociates,
leaving the LC3 intact on the luminal and exterior regions of autophagosome. LC3 is
12

regarded to play a role in the selective uptake of components to be degraded into the
autophagosome by interacting with molecules like p62/SQSTM1. This protein is a
multifunctional adaptor and binds to ubiquitinated cargos that are directed for clearance (41–
44). Rab 7 (GTPase of the Ras-related protein in brain (Rab) family), SNARE complex
(soluble N-ethylmaleimide sensitive fusion protein receptor) and lysosome-associated
membrane proteins 1 and 2 (LAMP-1 and LAMP-2) along with other factors directs the
autophagosome-lysosome fusion forming the autolysosome (45,46). The cargo loaded into
the autolysosomes then undergoes degradation in the acidic lysosomal environment by the
hydrolytic enzymes and the degraded products are recycled.
Impaired lysosome acidification has been implicated to be fatal in multiple cell types
like neurons, hepatocytes, and cardiomyocytes (47–49). The acidic luminal pH (4.5-5) is vital
for the maturation and hydrolytic activity of lysosomal enzymes and efficient lysosomal
function. Even a slight increase in pH would be detrimental and could result in cell death.
Lysosomes contain more than 60 degradative enzymes responsible for breaking down the
unfolded proteins, damaged organelles, amino acids, and fatty acids. Myocytes being postmitotic cells, are considered mostly irreplaceable and are vulnerable to pathological changes.
Absence of replication compel these cells to rely on the recycling processes for their survival.
Hence lysosomal integrity and functional autophagy are crucial for the smooth functioning of
cardiomyocytes. Depressed autophagy in cardiomyocytes leads to the accumulation of the
ubiquitinated intracellular cargo meant to be recycled and increases ROS production (50).
Lysosomal dysfunction has been reported in several cardiac complications. Lysosome
storage disorders (LSDs) manifest as hypertrophic and dilated cardiomyopathy, coronary
artery disorders, and valve defects in the heart. Dysregulations in lysosome biogenesis also
contribute towards the development of cardiovascular complications (51). Transcription
factor EB (TFEB) regulates the expression of lysosomal proteins and the genes involved in
lysosome biogenesis. Decreased expression of TFEB has been linked to cardiac
proteinopathy and cardiomyocyte death (51). DOX-induced inhibition of lysosomal
acidification blocks the autophagic flux in cardiomyocytes and led to the accumulation of
autolysosomes in in vivo mice models (52). Stimulating basal autophagy have been reported
to protect cardiomyocytes from DOX-induced toxicity probably by eliminating the
dysfunctional mitochondria and other organelles and hence reducing ROS production (28).
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Figure 1.5: Schematic representation of Autophagy. Autophagy begins with the formation
of an initiation membrane, which develops into a phagophore and elongates to form an
autophagosome carrying the cellular debris. Lysosome fuses with the autophagosome
forming the autolysosome and the proteolytic enzymes within this structure breaks down the
cargo which is then released into the cytosol and recycled.
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1.5 V-ATPase
Intracellular pH maintenance is accomplished with the help of ion channels, receptors,
transporters and pumps (53). The maintenance of the acidic pH gradient in the lysosomes is
achieved through the activity of vacuolar ATPase (V-ATPase), an ATP dependent
membranous proton pump highly conserved among eukaryotes. It was initially identified and
characterised in the yeast, Saccharomyces cerevisiae and is structurally similar to the
bacterial ATP synthase, F-ATPase (54). Apart from acidification of lysosomes and
endosomes, plasma membrane V-ATPases are also involved in other functions such as sperm
maturation and bone resorption (55). It has also been associated with cellular processes such
as signalling, membrane fusion, membrane trafficking, protein degradation, nutrient
homeostasis etc. (56). This multimeric protein has a cytosolic domain V1 and a membrane
domain V0 that undergoes reversible coupling to transport protons into the lysosomal lumen.
ATP hydrolysis occurs at the subunits of V1 domain which generates the energy required for
the translocation of protons through the membrane bound V0 domain subunits. In yeast, low
glucose, low pH and low salt concentrations prevents the assembly of the domains as a
measure to conserve ATP and prevent energy expenditure. It has also been shown that
increased extracellular pH prevents glucose mediated disassembly of V0 and V1 (57).
Contrastingly, in mammalian cells, low glucose and amino acid starvation has shown to
increase the V-ATPase activity probably to increase the autophagic flux and recycle amino
acids within the cell (58).

1.5.1 V-ATPase Structure
Mammalian V1 domain is water-soluble and comprised of 8 subunits A, B, C, D, E, F,
G and H. The membrane embedded V0 domain subunits include a, c, c″, d, e, ATP6AP1 and
ATP6AP2. Three copies each of A and B subunits of the cytosolic V1 are arranged as an
alternating hexamer. The D and F subunit forms the rotating central stalk (rotor) of the VATPase pump. The E and G subunits exist as three heterodimers forming the peripheral stalk
(stator) connecting V1 to subunit a of V0. The conformational changes of the linker protein
subunit H act as switch in controlling the reversible assembly of V1-V0 and prevents ATPase
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activity of the pump. The hydrophobic c ring of V0 comprises of nine copies of c and one
copy of c″ subunits each containing a single glutamate buried residue which undergoes
reversible protonation to translocate protons into the lysosomal lumen. Subunit d links the
proteolipid c ring to the rotating central stalk. The transmembrane subunit a binds to subunits
H, C and the peripheral stalk in the intact V-ATPase pump. It conducts proton to the
glutamate residues of the c ring and enables its exit at the luminal side via two hemi-channels
facing the cytoplasmic and luminal side, respectively. Subunit e occupies an adjacent position
to subunit a and is highly hydrophobic but its function in mammalian cell remains unknown.
ATP6AP1 and ATP6AP2 are two transmembrane accessory proteins located within the c
ring. ATP6AP1 acts as a regulatory protein and is involved in vesicular trafficking and bone
resorption in osteoclasts. ATP6AP2 is a pro renin receptor and is thought to contribute to VATPase mediated control of the renin-angiotensin pathway in regulating blood pressure and
electrolyte balance (58–60).
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Figure 1.6: Structure of mammalian V-ATPase. The mammalian V-ATPase pump has a
membrane-embedded V0 domain and a cytosolic V1 domain. V1 has eight subunits (A-H) and
V0 contains five subunits (a, c, c’, d, e). ATP6AP1 and ATP6AP2 are the accessory proteins
within the c ring of V0. ATP hydrolysis at V1 generates the energy for the transport of protons
into the lumen by the V0.
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1.5.2 V-ATPase Isoforms
Multiple subunit isoforms of mammalian V-ATPase have been identified and
characterised. Mammalian cells express four isoforms of subunit a and two each of subunits d
and e of the V0 domain. There are three isoforms of C and G of the V1 domain and two each
of subunits B and E. V0a is an integral membrane protein of ∼110 kDa having a cytosolic Nterminal and 9 transmembrane domains and is the largest subunit of the V0 domain. The
targeting of V-ATPase to the membrane of different cell types is achieved by this subunit.
Although ubiquitous, the expression of V0a1 is high in the brain, localised mainly on the presynaptic membrane and synaptic vesicles and is implicated in the acidification of these
vesicles. Neuronal cells and endothelium are enriched with V0a2 and it is found on the
intracellular Golgi vesicles. Membranes of lysosomes, osteoclasts and secretory vesicles of
pancreatic islet cells express V0a3 and this isoform is crucial mediator of the bone resorption
mechanism. V0a4 is almost exclusive to the renal cells of the kidney and also found in the
inner ear and epididymis (61,62). V0d1 occurs ubiquitously and V0d2 is predominantly
expressed in the kidney, osteoclasts, and lungs. It is nearly 40 kDa and is considered as one of
the linker proteins between the V0 and V1 domain at the central stalk of the pump.
Heterologous overexpression of this subunit improves the coupling efficiency of the VATPase pump (63). Two isoforms of the V0e subunits exist, e1 being ubiquitous and e2 found
in the brain. V1B1 and V1B2 are of nearly 56 kDa, the former being expressed in the kidney,
ear and lung and the latter being ubiquitous with enriched expression in the osteoclasts. V1C
is around 42 kDa and among its isoforms, C1 is ubiquitous. C2a and C2b are specific to lung
and kidney, respectively. V1E has a molecular weight of 31 kDa and E1 is testis specific
while E2 is ubiquitous.V1G occurs as a heterodimer with V1E and is of 13 kDa. Among its
isoforms, the ubiquitous one is V1G1. V1G2 and V1G3 are expressed in the brain and kidney
respectively (54,64).
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1.5.3 V-ATPase proton transport mechanism
The proton transport mechanism begins with the assembly of the V1 and V0 domains.
ATP hydrolysis occurs at the catalytic sites of the A3B3 hexamer enabling the rotation of the
central stalk. The proteolipid c ring attached to the central stalk rotates relative to subunit a
held stationary by the peripheral stalk. Protons enter subunit a through the cytoplasmic hemichannel and protonates the glutamate residues on the c ring which rotates and reaches the
luminal hemi-channel. Deprotonation of these residues occur by interaction with a conserved
arginine residue of subunit a releasing a proton to the hemi-channel facing the luminal side.
For every three ATPs hydrolysed at V1 domain, ten protons are translocated to the lumen
(58,60,65–68). Numerous studies have established the importance of functional V-ATPase in
maintaining the autophagic flux, the measure of autophagic degradation activity in the cell.
The outcomes observed with the loss of V-ATPase activity and inhibition of lysosome
acidification are the formation of enlarged autolysosomes resembling yeast vacuoles mutant
for peptidases (69,70).

1.5.4 V-ATPase Reversible assembly in mammals
Upon various stimuli such as environmental stress and nutrient depletion, cellular
homeostasis must be maintained in mammals by upregulating the recycling capacity of the
cells. The rate of autophagy or autophagic flux is enhanced and lysosomal degradation of
ubiquitinated cellular debris is increased so that the amino acids, fatty acids, and other
molecules are available back in the cytoplasm so that it can be metabolised to generate
energy. Based on the requirement, the V-ATPase pump acidifies the lysosomes to achieve
optimal recycling capacity. The rotation driven proton pumping mechanism of V-ATPase is
tightly regulated by the reversible dissociation of the V1 and V0 domains. Though initially
described in yeast, a similar mechanism applies to mammalian cells as well.
In response to glucose starvation in mammals, AMPK activity and the
phosphatidylinositol 3-kinase/Protein kinase B (PI3K/Akt) signalling pathway activate the
assembly of V0 and V1 domains, increasing the proton transport and re-establishing the
optimal lysosomal pH. During disassembly, V1C dissociates from the V1 domain and
separates it from V0. The structure of the C resembles a collar and a transient phosphorylation
at this subunit is predicted to control its interaction with V1E, V1G and V0a. V1H undergoes a
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conformational change to inhibit the ATP hydrolysis at V1 preventing ATP expenditure and
blocks the proton transport at V0. V1, devoid of the C subunit is found in the cytoplasm as a
free water-soluble protein and V0 remains membrane bound (Figure 1.7) (58,67,71).

Figure 1.7: V-ATPase activity is tightly regulated by reversible disassociation of V0 and
V1 domains. Upon nutrient depletion, subunit C detaches from cytoplasmic V1 domain, and
separates it from the membrane bound V0 domain. Subunit H undergoes a conformational
change and hinders ATP hydrolysis at V1 and hence conserves energy. The rotation of the
stalk and proton transport at the V0a is stalled and the V-ATPase pump becomes inactive.
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1.5.5 V-ATPase inhibitors
Malfunctional V-ATPase activity have been reported in multiple pathological
conditions conferring this ubiquitous pump the status of an attractive therapeutic target. A
handful of V-ATPase inhibitors have so far been identified and are available in the market
allowing researchers to further study the scope of V-ATPase modulation that could be
translated to clinical settings. Bafilomycin A and concanamycin A were the first among a
handful to be identified in the 1980’s and was isolated from the Streptomyces sp. These
pleco-macrolide antibiotic V-ATPase inhibitors are characterised by a 6-membered
hemiacetal ring connected to the macrolactone ring by a C3 spacer. The macrolactone
antibiotic archazolid also inhibits V-ATPase and is highly toxic to cells. Archazolid A has a
macrocyclic lactone ring with a thiazole side chain and is produced by the myxobacteria
Archangium gephyra and Cystobacter violaceus. Bafilomycin A, concanamycin A and
archazolid inhibits V-ATPase by binding specifically to the subunit c of V0 (72–74).
A relatively new class of V-ATPase inhibitors were identified in the late 1990’s and
they shared a common benzolactone enamide structure. Salicylihalamides, lobatamides,
oximidines and apicularens belonged to this group and were isolated from natural microorganism sources. They were peculiar in their inability to inhibit V-ATPases of fungal origin.
The benzolactone enamide apicularen binds to the interface of the subunits a and c of the
membrane embedded V0 domain stalling the proton transport. Natural compounds of plant
origin, Diphyllin and Celangulin V also inhibited V-ATPase activity in vitro. Though the
mechanism of inhibition by Diphyllin has not been well characterised, Celangulin V binds to
the subunits a, H, and B of V-ATPase (73,75–77).
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Figure 1.8: Structures of V-ATPase inhibitors. The V-ATPase inhibitory capabilities of
Bafilomycin, Concanamycin, Archazolid and Apicularen have been characterised and are
used as pharmacological tools for studying lysosome function and autophagy
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1.5.6 Bafilomycin A
Bafilomycin A disrupts autophagy by inhibiting lysosomal acidification and
autophagosome-lysosome fusion. It was quite recently reported that the Bafilomycin A
inhibits the autophagosome-lysosome fusion via its effects on the Ca2+ transporter pumps.
The proton transport mechanism of V-ATPase is blocked by this macrolide by binding to the
subunit c of the V0 domain. Other ATPases such as ATP2A/SERCA are also moderately
inhibited by this antibiotic (78–80). Though its clinical use is limited because of toxicity,
Bafilomycin A serves as an important pharmacological tool to study autophagy.

Figure 1.9: Bafilomycin A inhibits the proton transport mechanism of V-ATPase.
Bafilomycin A inhibits V-ATPase pump and prevents lysosome acidification and stalls the
autophagic machinery in cells.
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1.5.7 V-ATPase activity in the heart
Decreased V-ATPase activity have been linked to contractile dysfunction in
cardiomyocytes. Excessive lipid accumulation impairs the endosomal pump activity and
leads to cardiac insulin resistance in rodents and human cardiomyocytes. It is speculated that
lipids induce V-ATPase disassembly into V0 and V1 and migration of V1 into the cytoplasm.
In response, the long chain fatty acid transporter CD36 in the heart, stimulated by insulin,
translocates to sarcolemma from endosomes leading to further increase in up-take and storage
of triacylgycerols and elicit insulin resistance (49). Proper regulation of endosomal pH is
necessary for directed translocation of glucose transporters (GLUT) in the heart as well.
Restoring V-ATPase activity has been hence considered as a promising strategy to combat
lipid-induced cardiomyopathy (81).
High-density lipoproteins (HDL) are generally considered as the “good” cholesterol
as it aids in reverse cholesterol transport from the tissues to the liver for elimination. The
anti-atherogenic property of HDL is mainly attributed to its major component Apolipoprotein
A1 (ApoA1). ApoA1 accepts the cell cholesterol with the help of the cell membrane protein
ATP-binding cassette A1 (ABCA1) and generates nascent HDL. Activation of ApoA1 occurs
when it’s lipidated causing the N-terminal to unfold and spontaneously react with the
membrane lipids and release nascent HDL from the cell. ABCA1 mediated recruitment of VATPase to the cell surface promotes acidification increasing the membrane lipid fluidity and
N-terminal unfolding of ApoA1. Thus V-ATPase modulation helps in HDL biogenesis and
cholesterol efflux and provides protection from coronary heart disease (82). DOX treatment
has been reported to disrupt the basal autophagic flux by inhibiting the lysosomal V-ATPase
activity and decreased cardiomyocyte cell survival. Increased lysosomal pH in
cardiomyocytes led to the accumulation of autolysosomes and exacerbated oxidative stress
(83),(52). Though DOX mediated inhibition of lysosomal acidification has been proved in
cardiomyocyte lysosomes, the exact mechanism of V-ATPase modulation remains unclear.

24

1.6 Nicotinamide Adenine Dinucleotide (NAD+)
NAD+ is a major coenzyme present within all living cells and is involved in various
essential cellular processes. It was discovered in boiled yeast extracts more than a century
ago by Sir Arthur Harden. NAD+, its phosphorylated form NADP, and reduced forms NADH
and NADPH, are important cofactors in the energy producing and metabolic processes within
the cell (84). NAD+ pools within the mammalian cell occur in the cytosol, nucleus,
mitochondria, endoplasmic reticulum and Golgi network (85). NAD+ consuming enzymes in
the cell are sirtuins, poly ADP-ribose polymerases (PARPs) and CD38/157 ectoenzymes.
Seven mammalian sirtuins have been identified till date and they are involved in many
cellular pathways. These proteins are evolutionarily conserved and belong to class III protein
deacetylase family, which are the only histone deacetylases requiring NAD+ for their
activity. Sirtuins cleave NAD+ forming nicotinamide (NAM) and the acetyl group of the
substrate protein is transferred to the ADP-ribose moiety of NAD+ producing O-acetyl-ADPribose and the deacetylated substrate (86). The PARP family of proteins are involved in polyADP ribosylation i.e., the transfer of ADP-ribose to target proteins. Members of this family
are involved in many vital cellular processes such as DNA synthesis and repair, nucleic acid
metabolism and chromatin structure modulation (87). CD38 and CD157 are considered as
ectoenzymes, a family of enzymes having an extracellular catalytically active site. These
proteins catalyse the conversion of NAD+ to cyclic ADP-ribose, an important secondary
messenger in calcium signalling. They are mainly expressed in immune cells and are also
involved in cell adhesion and migration (88).
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Figure 1 10: Structure of NAD+.

1.6.1 NAD+ Biosynthesis
The major precursors and intermediates involved in the biosynthesis of NAD+ are
tryptophan, nicotinamide, nicotinic acid, nicotinamide riboside and nicotinamide
mononucleotide. These are obtained either from the diet or by the intracellular NAD+
catabolism. The Preiss-Handler pathway utilizes the enzyme Nicotinic acid
phosphoribosyltransferase (NaPRT) to convert dietary Nicotinic acid or Vitamin B3 to
NaMN (Nicotinic acid mononucleotide). NaMN/NMN adenyltransferases (NMNATs)
converts NaMN to nicotinic acid dinucleotide (NAAD). NAD+ is amidated from NAAD by
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NAD+ synthetase enzyme (NADS). The de novo pathway involves the essential amino acid
tryptophan which is metabolised to Quinolinic acid (QA) via the kynurenine pathway in the
liver. It is then converted to NaMN by Quinolinic acid phosphoribosyltransferase (QAPRT)
and then to NAD+ using the Preiss-Handler pathway. The contribution of the de novo
pathway towards NAD+ pool in mammals is negligible as tryptophan metabolism contributes
to other cellular processes as well. Mammalian NAD+ synthesis occurs mainly via the
salvage pathway involving the conversion of Nicotinamide (NAM), produced from NAD+
consuming reactions, to Nicotinamide mononucletide (NMN) by the rate-limiting enzyme
Nicotinamide phosphoribosyltransferase (NAMPT). NAM is the by-product of NAD+
breakdown by sirtuins, PARPs and CD38/157 ectoenzymes. NAMPT is also activated by
AMPK, the autophagy stimulating kinase in cells. Nicotinamide Riboside (NR), a Vitamin
B3 derivative, also contributes to the NMN pool by Nicotinamide riboside kinase (NRK)
mediated enzymatic phosphorylation. Two isoforms of NRK have been discovered, the
ubiquitously expressed NRK1 and the skeletal muscle specific NRK2. NMN is then
converted to NAD+ by NMNAT. Three isoforms of NMNAT have been identified so far and
they differ in their sub-cellular location and catalytic actions. The ubiquitously expressed
NMNAT1 is predominantly found in the nucleus. NMNAT2 is mostly brain-specific and
localised in the cytosol and Golgi compartments. NMNAT3 is mitochondrial specific, found
in liver, heart, skeletal muscle and also in red blood cells (84,89–92).
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Figure 1.11: Schematic illustration of NAD+ biosynthesis in mammalian cells.
NaPRT- Nicotinic acid phosphoribosyltransferase; NMNAT- NaMN/NMN
adenyltransferases; NADS- NAD+ synthetase; QAPRT- Quinolinic acid
phosphoribosyltransferase; NRK- Nicotinamide riboside kinase; NAMPT- Nicotinamide
phosphoribosyltransferase (rate-limiting enzyme) (93).
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1.6.2 NAD+ in the heart
The half-life of NAD+ in mammalian cells is around 10 hours with mitochondrial
NAD+ accounting for nearly 70-75% of the total cellular content in heart cells (84). This is in
consistence with the high energy demands of the heart. The levels of the Nicotinic acid
converting enzyme NaPRT is low in heart and hence Nicotinamide mediated NAD+
biosynthesis is thought to be the predominant source of the co-enzyme. NAD+ depletion has
been reported in multiple pathologies associated with the heart. Supplementing NAD+ has
been reported to protect the heart in in vivo models of heart failure. Restoring NAD+ levels in
the ischemic and hypertrophic heart prevents disease progression and decreases the risk of
heart failure (94). Despite the promising therapeutic effect of NAD+ upregulation in the
heart, the protective mechanism in various cardiovascular pathologies remains largely
unanswered. Protein hyperacetylation in failing myocardial cells was attributed to the
unavailability of NAD+ for sirtuin-mediated deacetylation. Altered energy metabolism and
decreased NAD+ biosynthesis was also observed in models of failing heart. NAD+
precursors reduced the protein acetylation, restored the energy metabolism and increased the
synthesis of NAD+ in the heart thereby preventing further damage to the organ (95).
The delicate balance between NAD+ synthesis and consumption in the cells are
altered during pathological conditions. NAD+ levels in the cell increase during energylimiting conditions such as fasting, calorific restriction, low glucose diets or exercise. High
fat and high glucose diets as well as oxidative stress deplete NAD+ levels in the cell and
affect downstream cellular processes (94). Boosting NAD+ levels has been reported to
ameliorate multiple pathological conditions such as diabetes, cardiovascular diseases,
neuropathies and age-related cellular dysfunction (96). NAD+ inhibition also blocks
autophagic flux (97) and so maintaining the balance between the consumption and synthesis
is essential for cellular integrity.

1.6.3 Role of NAD+ in Autophagy
Autophagy plays a central role in maintaining cellular homeostasis particularly in
post-mitotic cells like cardiomyocytes. NAD+ is essential for sustaining the basal autophagic
machinery in these cells (98). NAD+ is reduced to NADH to facilitate cellular ATP
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generation through glycolysis in the cytosol, and via the tricarboxylic acid cycle in the
mitochondria. Imbalances in the NAD+/NADH ratio affect ATP generation and activate the
AMPK pathway and autophagy. NAD+ can be phosphorylated to NADP+ and then get
converted to NADPH which catalyses the formation of the antioxidant glutathione. Reduction
in glutathione levels upsets the redox balance in the cell and activates AMPK. NAD+
depletion and ROS can impair the autophagic machinery by influencing post-translational
modifications of autophagy-related proteins. During pathological conditions, PARPs and the
CD38/157 ectoenzymes are hyperactivated, and consume the intracellular NAD+ pools
leading to its depletion. PARPs consume nearly 10 - 20% of NAD+ within minutes of DNA
damage. Sirtuin activity is hence reduced and so are the deacetylation processes which are of
crucial significance in the regulation of autophagy-related proteins, transcription factors and
receptors. Acetylation of transcription factor EB (TFEB), the master regulator of lysosome
biogenesis, has been linked to its inability to bind to DNA and negative regulation of
lysosomal genes. Though acetylation and deacetylation related functional regulation of
multiple other autophagic proteins such as ULK1 and ATG 3,7,5 and 12 have also been
identified, the list does not tend to be exhaustive. PARP activation also inhibits mitochondrial
ATP synthesis by inactivating sirtuins and induces autophagy by activating the AMPK
pathway (85,99).

1.6.4 Nicotinamide mononucleotide (NMN)
Nicotinamide mononucleotide (NMN) or Nicotinamide-1-ium-1-β-D-ribofuranoside
5′-phosphate is an intermediate in the NAD+ biosynthesis pathway and it is formed by the
reaction between nicotinamide (NAM), a phosphate group and a nucleoside containing a
ribose moiety. NMN is also formed from NR by enzymatic phosphorylation (Figure 1.11). It
has a molecular weight of 334.221 g/mol and exists as two anomers, alpha and beta, the latter
being the active form (100). Being a Vitamin B3 derivative, NMN is naturally found
abundantly in vegetables like cabbage, broccoli, and cucumbers and in fruits like avocados
and tomatoes. The amount of NMN in various food sources has been summarised in Table 2
(101). NMN absorption from food sources begins in the gut within 2-3 minutes where it
undergoes dephosphorylation by CD73 to NR and enters the cells with the aid of nucleoside
transporters. In the cells, NR is converted back to NMN to synthesize NAD+. Recently, a
specific NMN transporter has also been identified in cells, encoded by the gene Slc12a8 that
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is highly expressed in the small intestine. Knocking down this gene using lentiviruses in mice
significantly reduced the plasma availability of NMN compared to the control. The Slc12a8
NMN transporter has a molecular weight of nearly 90 kDa and is sodium ion dependent
(100,102).

Figure 1.12: Structure of β-NMN. Nicotinamide mononucleotide has a phosphate group,
Nicotinamide base and ribose sugar

NMN enhanced NAD+ levels and reversed impaired glucose tolerance and improved
insulin sensitivity in rodent models of obesity and diabetes (103,104). NMN administration
also prevented ischemic-reperfusion injury in the heart and cerebrum mediated by the sirtuin
pathway (105,106). NMN supplementation has been successful in ameliorating alcoholic
liver disease, acute kidney injury, retinal degeneration, cerebral haemorrhage and cognitive
impairment in animal models (107). Mitochondrial protein hyperacetylation has been
implicated as a causative factor in heart failure. Elevation in the NADH/NAD+ ratio induces
mitochondrial protein hyperacetylation and increases the sensitivity of the mitochondrial
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permeability transition pore. NMN reverses hyperacetylation and normalizes the NAD+
redox balance in the heart (108). It also improved cardiac function and bioenergetics in a
sirtuin dependent manner in rodent models of cardiomyopathy and so NMN has been
evaluated as a potential drug in the treatment of cardiac dysfunctions (109).

Table 2: Natural sources of NMN
Source

mg/100 g

Broccoli

0.25 - 1.12

Cabbage

0.0 - 0.90

Avocado

0.36 - 1.60

Cucumber

0.56 - 0.65

Tomato

0.26 - 0.30

Mushroom

0.0 - 1.01

Raw beef

0.06 - 0.42

Shrimp

0.22

1.7 Rationale
Autophagic stimulation improves cardiac function by recycling the misfolded and
dysfunctional proteins (110). Post-mitotic cells like cardiomyocytes rely highly on the
lysosomal recycling mechanisms as they cannot simply be discarded when non-functional,
owing to their limited potential to divide (111). Maintaining the autophagic flux in
cardiomyocytes is hence beneficial to promote the longevity and functioning of these cells.
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Stress triggers autophagic flux in cells to sustain the metabolic demand and organelle
biosynthesis (112). Increased NAD+ synthesis maintains autophagic flux by activating sirtuin
deacetylases (97). Sirtuins are implicated in aging, metabolism, and stress. The most
extensively studied mammalian sirtuin, SIRT1, has been liked to transcriptional regulation
and DNA repair as well (113). The deacetylase activity of sirtuins are attributed to their
catalytic pocket having a conserved zinc tetra-thiolate motif (114). SIRT1 inhibition
suppresses autophagy in cardiomyocytes and NAD+ enhances SIRT1 in the nucleus
modulating the transcription of proteins regulating autophagy (115). SIRT1 expression is
downregulated with DOX treatment and overexpressing this protein attenuates cardiac
dysfunction (116). Our lab has previously reported that the NAD+ precursor, Nicotinamide
Riboside (NR) prevented DOX induced accumulation of autolysosomes in mouse hearts and
cultured cardiomyocytes by maintaining lysosomal acidification via NAD+/Sirt1 signalling
(117). It is probable that the maintenance of autophagic flux by sirtuins in cardiomyocytes
could be at least to some extent, attributed to the maintenance of lysosomal activity. Upregulation of the mitochondrial sirtuins has been demonstrated to accelerate the impaired
mitophagy by deacetylating the F0-F1 ATPase proton pump in mitochondria (118,119). F0F1 ATPase and the lysosomal V-ATPase are closely related in terms of structure and function
and could have evolved from a common ancestor (120).
Our lab has identified hyperacetylation of the d1 sub-unit of V0 domain (ATP6V0d1) in
response to DOX treatment. It could be speculated that the protective role of NAD+ upregulation in DOX-induced cardiotoxicity could be in part via the deacetylation of the VATPase pump subunits. NAD+ precursors like NMN are easily soluble and orally
bioavailable and so have been widely researched on rodent models and have entered clinical
trials as well (121). This study determines the potential and mechanism of NAD+ and its
precursor, NMN, in preventing DOX-induced changes in lysosomal acidification and hence
cardiotoxicity in an in-vitro model.
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1.8 Hypothesis
I hypothesize that
A) Doxorubicin increases lysosomal pH in H9c2 cells and induces cardiotoxicity.
B) Boosting NAD+ using NMN will prevent DOX-induced increases in lysosomal pH
and protect H9c2 cells from DOX toxicity.

A

B

Figure 1.13: Schematic illustration of Hypothesis. A) DOX treatment inhibits lysosomal
acidification in H9c2 cells by depleting NAD+ levels and induce cardiotoxicity. B) Boosting
NAD+ using NMN maintains the acidic lysosomal pH and protects H9c2 cells from DOXinduced toxicity.
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1.9 Specific Aims
1. Determine dose-dependent effect of DOX on H9c2 cells.
2. Determine the effect of DOX on the lysosomal pH of H9c2 cells.
3. Analyse the potential of NMN in preventing DOX- induced toxicity in H9c2 cells.
4. Determine the mechanism by which NMN prevents DOX-induced increases in
lysosomal pH.
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Chapter 2
2 Materials and Methods
2.1 H9c2 cell culture
H9c2 (2-1) (CRL-1446) cells were procured from American Type Culture Collection
(ATCC). Cells up to passage 15 were used for this study. The cells were grown in a culture
flask incubated at 37℃ in a 5% CO2 humidified air atmosphere. The growth media used was
high Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% heatinactivated fetal bovine serum (FBS), penicillin 100 IU/mL, and streptomycin 10 µg/mL.
Sub-culturing was done every three days when confluency of 70-80% was attained. Briefly,
the media in the flask was discarded and the cells were washed once with D-Hank’s solution
(Table 3). The cells were then incubated with 0.25% Trypsin at 37℃ for 1-2 minutes. Fresh
growth media containing 10% FBS was added to the flask to terminate the trypsinization
process, and then cells were centrifuged at 125 x g for 5 minutes. The trypsin containing
media was discarded and cells were suspended in fresh growth media and re-plated.

Table 3: D-Hank’s Solution (1L)

KCl

0.4 g

KH2PO4

0.06 g

NaCl

8g

D-Glucose

1g

Phenol red

0.012 g

36

2.2 Isolation and culture of neonatal cardiomyocytes
Primary neonatal cardiomyocytes were isolated from neonatal mice born within 24
hours. Neonatal mice were wiped with 75% alcohol and then killed by decapitation. The
chest was cut open at the sternum and the hearts were harvested into D-Hank's solution
(Table 1) in a 50 mL tube. The hearts were rinsed in D-Hank's solution twice to remove the
blood. Each heart was then divided into 5–6 pieces using a surgical blade and then rinsed
again in D-Hank's solution. It was then subjected to the following 3 rounds of digestion;
(1) Heart sections were incubated in Liberase Blendzyme (2.5 mg/mL, Roche Applied
Science) for 10 minutes at 37°C in a water bath and the supernatant was discarded.
(2) The sections were again incubated in fresh Liberase Blendzyme solution at 37°C for 15
min with gentle swirling every 5 min. After 15 min, the heart sections were minced to isolate
the cardiomyocytes completely. The supernatant containing isolated cardiomyocytes was
collected and the digestion was terminated by adding the culture medium, DMEM,
supplemented with 10% new-born calf serum (NBCS).
(3) The precipitate was again incubated with fresh Liberase Blendzyme and the digestion
procedure was repeated.
The supernatant was then pooled with the earlier one and centrifuged at 200 x g for 5
minutes. The precipitate containing the isolated cardiomyocytes were resuspended in 10%
NBCS supplemented DMEM. The cells were then seeded in a culture plate and placed in a
CO2 incubator at 37°C for 120 minutes which allowed fibroblasts to adhere to the plate. After
fibroblast adherence, cardiomyocytes were collected and counted. The cardiomyocytes were
then seeded into a culture plate, coated with 1% gelatin and incubated in a CO2 incubator at
37°C. The cardiomyocytes were utilized for experiments after 18 hours. The purity of
neonatal cardiomyocytes was characterized by the staining for troponin and was more than
95%.
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2.3 Doxorubicin Cardiotoxicity- in vitro experimental model
H9c2 is an adherent cell line derived from the subclone of the ventricular part of the
embryonic BD1X heart tissue of Rattus norvegicus and exhibits skeletal and cardiac muscle
properties. It is a cell model used as an alternative for cardiomyocytes (122). H9c2 cells and
neonatal cardiomyocytes were seeded in multi-welled culture plates at densities required for
the assays and incubated at 37℃ in a 5% CO2 humidified air atmosphere. When desired
confluency was attained (12-18 hours), cells were treated with NMN or NAD+ for 24 hours
followed by DOX/Bafilomycin A/DOX-Bafilomycin A treatment for further 24 hours.
Control cells were supplemented with fresh growth media and were devoid of any treatment
throughout the duration of experiment.

Figure 2.1: Schematic representation of the in vitro model used for study.

2.4 CCK-8 Assay
Cell counting kit-8 (CCK-8) (Dojindo Molecular Technologies, Inc), a colorimetric
assay, was used to determine the cell viability. The water-soluble tetrazolium salt, WST-8, is
reduced by the dehydrogenases in living cells to a yellow colour formazan dye which is
measured at an absorbance of 450 nm. H9c2 cells were seeded in a 96-well plate at a density
of 10,000 cells per well. After treatment with various drugs, 10 µL of CCK-8 solution,
provided by the manufacturer, was added to each well. The plate was incubated at 37°C for
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1-4 hours. The absorbance was measured at 450 nm using iMark™ Microplate Absorbance
Reader (Bio-Rad Laboratories Inc). The intensity of the yellow dye is directly proportional to
the number of living cells. Percentages of viable cells were calculated using the formula:
Cell viability % = Abs450 sample – Abs450 blank X 100
Abs450 control - Abs450 blank

2.5 Lactate Dehydrogenase Release Assay
Lactate Dehydrogenase (LDH) is soluble enzyme released from cells due to
compromised cell membrane integrity. LDH enzymatically converts iodonitrotetrazolium to a
red coloured formazan dye which can be detected using a colorimetric assay at an absorbance
of 490 nm. The amount of LDH release is directly proportional to cell damage. LDHCytotoxicity Colorimetric Assay Kit (Takara Bio Inc) was used to detect the activity of LDH
released from H9c2 cells following treatment. The supernatant was collected in clear optical
96-well microtiter plates and incubated for 30 minutes at room temperature with the reaction
mixture containing catalyst and dye solution provided by the manufacturer. The reaction was
stopped using 1N HCl and the absorbance was measured at 490 nm using iMark™
Microplate Absorbance Reader (Bio-Rad Laboratories Inc).

2.6 Caspase-3 Activity
Caspase-3 belongs to the family of Cysteine-aspartic acid proteases and activation of
the enzyme is required for apoptotic cell death. Activated caspase-3 in cell lysates cleaves the
peptide substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC)
and releases fluorescent 7-amino-4-methylcoumarin (AMC) which can be detected at
excitation and emission wavelengths of 360 and 460 nm, respectively. Caspase-3 activity in
H9c2 cells was determined using the following protocol. Briefly, the cells were lysed using
ice-cold lysis buffer (Table 4) and the cell lysates were centrifuged at 10,000 x g for 10 min
at 4 °C. The supernatant was collected, and the protein concentration was measured using DC
protein assay based on manufacturer’s protocol (Bio-Rad Laboratories Inc). 100μg protein
was incubated with caspase-3 substrate Ac-DEVD-AMC and Ac-DEVD-AMC in the
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presence of inhibitor AC-DEVD-CHO diluted in assay buffer (Table 4) at 37°C for 2 hours.
Caspase-3 cleaves the substrate Ac-DEVD-AMC and releases chromophore AMC which can
be detected by a fluorescence spectrophotometer with excitation of 355 nm and emission of
460 nm.

Table 4: Lysis/Assay Buffer (100mL)
Reagent

Lysis Buffer

Assay buffer

HEPES (1 M, pH=7.4)

5 mL

5 mL

CHAPS

0.1 g

0.1 g

NaCl

-

585 mg

DTT (1 M)

500 µL

1 mL

EDTA (0.5 M)

20 µL

200 µL

NP-40

100 µL

-

Glycerol

-

10 mL

H2O

94.4 mL

83.8 mL

2.7 Lysosomal pH measurement
Changes in lysosomal pH were measured using LysoSensor yellow/blue DND-160
(Invitrogen). This dye imparts yellow fluorescence in acidic environments and blue
fluorescence in neutral pH in living cells. The ratio of emission at 460 and 535 nm was used
to interpret the pH. H9c2 cells were seeded in 96-well black clear bottom sterile plates at a
density of 5000 cells per well. After treatment, the cells were incubated with the dye (1 µM)
for 5 minutes at 37℃. The fluorescent signals were determined using a Spectra Max M5
Multi Mode Microplate Reader with excitation of 340 nm. The ratio of emission, 460/535
nm, was then calculated for each sample.
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2.8 Co-immunoprecipitation (co-IP) and Western Blot Analysis
Co-immunoprecipitation was done to pull down the acetylated proteins from neonatal
cardiomyocytes following DOX and NMN treatments. Cells were lysed using the lysis buffer
(Table 4) and disrupted by ultrasonication and centrifuged at 10,000 x g for 10 minutes at
4℃. Protein was quantified using DC protein assay (Bio-Rad Laboratories Inc) and 400 µg of
protein was subjected to immunoprecipitation. Briefly, Anti-acetyl Lysine antibody (abcam)
was used to pull down the proteins using Dynabeads™ Protein G Immunoprecipitation Kit
(Invitrogen) following the manufacturer’s instructions. The protein was then eluted from the
beads using the elution buffer supplied in the kit and subjected to SDS- polyacrylamide gel
electrophoresis followed by western blot analysis.
The immunoprecipitated protein was mixed with 6X loading buffer (Table 5) in a
microtube and incubated at 70℃ for 10 minutes on a dry bath for denaturing. The protein was
then subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
using a 4% stacking gel (Table 6) and 12% resolving gel (Table 7) using a BIO-RAD MiniPROTEAN system. 30 µL of proteins were added to the wells of the gel and resolved at
100V with in-house running buffer (Table 8) till the running front reached the end of the gel.

Table 5: 6X Loading Buffer (100 mL)
Tris-HCl (1M, pH 6.8)

37.5 mL

SDS

6g

Bromophenol blue

30 mg

Glycerol

48 mL

β-Mercaptoethanol

9 mL

H2O

5.5 mL
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Table 6: 4% Stacking gel (6 mL)
H2O

4.10 mL

30% Acrylamide

1 mL

Tris (1.5M, pH 6.8)

0.75 mL

10% SDS

60 µL

10% Ammonium Persulphate

60 µL
6 µL

TEMED

Table 7: 12% Resolving Gel (20mL)
H2O

4.10 mL

30% Acrylamide

8 mL

Tris (1.5M, pH 8.8)

7.5 mL

10% SDS

200 µL

10% Ammonium Persulphate

200 µL
8 µL

TEMED

Table 8: Running Buffer pH 8.3 (1L)
Tris Base

3.03 g

Glycine

14.41 g

SDS

1g

H2O

1L

β-Mercaptoethanol

9 mL
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The proteins were then transferred from the gel on to a poly vinyl difluoride (PVDF)
membrane (Froggabio) by tank blotting in ice-cold transfer buffer (Table 9) at 25 V for 15
hours using the Bio-Rad Mini Trans-Blot electrophoretic transfer cell. The membrane was
then blocked using 5% non-fat milk (Bio-Basic) in TBST (Table 10) at room temperature for
1 hour. After blocking, the membrane was incubated overnight at 4℃ with primary antibody
at manufacturer recommended dilution dissolved in 5% BSA. The membrane was then
washed 3 times with TBST for 10 minutes each followed by incubation with secondary
antibody dissolved in 5% non-fat milk in TBST for 1 hour at room temperature. After
washing the membrane again 3 times for 10 minutes each in TBST, the proteins on the
membrane were visualised using a chemiluminescence detection system using enhanced
chemiluminescence reagent (Table 11).

Table 9: Transfer Buffer (1L)
Tris base

3.03 g

Glycine

14.41 g

Methanol

200 mL

H2O

800 mL

Table 10: TBST pH 7.6 (1L)
Tris base

2.42 g

NaCl

8g

H2O

1000 mL

Tween 20

1 mL
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Table 11: Enhanced Chemiluminescence (ECL) Reagent (200mL)
Component

Reagent A

Reagent B

Tris-HCl (1M, pH 8.5)

100 mL

100 mL

Coumaric acid (90 mM)

440 µL

-

Luminol (250mM)

1 mL

-

H2O2

-

60 µL

2.9 Statistical Analysis
Statistical Analysis was done using Graphpad Prism software version 6.0. All data
were presented as mean ± standard deviation (SD). One-way analysis of variance (ANOVA)
was used for analysing the results. Post-hoc comparisons were done using Tukey HSD or
Dunnett’s Test as appropriate. A value of P < 0.05 was considered statistically significant.
The test used for each experiment has been mentioned in the figure legend.
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Table 12: Reagent Information
Reagent

Manufacturer

Cat #

DMEM

Gibco, USA

11995-065

DMEM

Wisent Inc, Canada

319010CL

HI FBS

Gibco, USA

12484-028

Penicillin-Streptomycin

Gibco, USA

15140-122

Trypsin-EDTA

Gibco, USA

25200-056

Liberase Blendzyme

05401151001

NBCS

Roche Applied Science,
Switzerland
Gibco, USA

Gelatin

Sigma, USA

G9382

Triton X-100

Sigma, USA

T9284

NaOH

VWR, USA

BDH7222-1

Tris

Bio Basic, Canada

TB0196

HCl

Sigma, USA

HX0603-4

KCl

Sigma, USA

PX1405-1

KH2PO4

Bio Basic, Canada

PB0445

NaCl

Bio Basic, Canada

DB0483

D-Glucose

Bio Basic, Canada

GB0219

Phenol red

Sigma, USA

P5530

SDS

Sigma, USA

L3771

Bromophenol Blue

Sigma, USA

20017

Glycerol

Sigma, USA

G5516

β-Mercaptoethanol

Sigma, USA

444203
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26010-074

Acrylamide

Bio Basic, Canada

AB1032

APS

Bio Basic, Canada

AB0072

TEMED

Bio Basic, Canada

TB 0508

Glycine

Bio Basic, Canada

GB0235

Methanol

VWR, USA

BDH1135-4LP

Coumaric acid

Sigma, USA

C9008

Luminol

Sigma, USA

A8511

HEPES

Bio Basic, Canada)

HB0264

CHAPS

Bio Basic, Canada)

CD0110

DTT

Bio Basic, Canada

DB0058

NP-40 Sigma

Sigma, USA

13021

Na2HPO4

Sigma, USA

S0876

β-NMN

Apex Bio, USA

B7878

NAD+, free acid

Calbiochem, Japan

481911

Bafilomycin A

Apex Bio, USA

A8627

Doxorubicin Hydrochloride

Mylan, USA

67457-436-50

EDTA

Sigma, USA

E5134

Table 13: Antibody Information
Antibody

Manufacturer

Cat#

Dilution

Anti-ATP6V0D1

Abcam, USA

ab202897

1:1000

Anti-Acetyl Lysine

Abcam, USA

ab22550

1:1000

Anti-GAPDH

Santa Cruz
Biotechnology, USA

sc-25778

1:1000
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Chapter 3
3 Results
3.1 DOX induces dose-dependent toxicity in H9c2 cells
The toxic effects of DOX on H9c2 cells have been reported from our lab and authors
elsewhere (117,123,124). Dose-dependent toxicity along with increased oxidative stress and
autophagic flux impairment have been confirmed by these authors. To confirm the toxic
effect of DOX on H9c2 cell viability and to determine the dose for further experiments, cells
were seeded in 96-well sterile plates at a density of 1000 cells per well. After 24 hours, the
cells were treated with DOX at concentrations of 0.5, 1, 2 and 5 µM. Control cells were left
untreated. About ~75% of cells were found to be viable with 0.5 µM DOX. 1 µM DOX
reduced the number of viable cells by nearly 50%. Less than 30% cells survived with 2 and 5
µM DOX treatment for 24 hours. As shown in Figure 3.1, DOX reduces cell viability in a
dose-dependent manner. As mentioned earlier, DOX has high affinity towards mitochondria
in cardiomyocytes and 0.5- 1 µM has been considered as clinically relevant plasma
concentrations where the mitochondrial accumulation is around 50 -100 µM (125).

47

*
*
*
*

Figure 3.1: DOX treatment decreased H9c2 cell viability in a concentration-dependent
manner. H9c2 cells were cultured in 96-well plates for 24 hours. The cells were then
incubated with DOX at concentrations of 0.5, 1, 2 and 5 µM or left untreated for another 24
hours. Cell viability was assessed using CCK-8 method. One-way ANOVA analysis followed
by Dunnett’s test was used to compare groups (n= 3 independent experiments) (*P<0.05
versus control)
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3.2 DOX increases LDH release in H9c2 cells
LDH is a stable cytoplasmic enzyme released into the cell culture medium upon
plasma membrane damage. H9c2 cells were seeded in 24-well plates and incubated for 24
hours. The growth media was replaced with DOX containing culture media at concentrations
of 1, 2 and 5 µM and incubated for another 24 hours. Control cells were left untreated. The
media containing LDH was collected and incubated with an equal volume of reaction mix
containing the catalyst and dye solution from the LDH-Cytotoxicity Colorimetric Assay Kit
(BioVision Incorporated). The LDH enzyme in the media oxidizes the lactate component of
the catalyst to pyruvate which in turn reacts with the tetrazolium salt of the dye solution
forming a red coloured formazan dye. This water-soluble formazan dye was detected by a
spectrophotometer at 490nm which corelates with the LDH activity in the cells. DOX at all
the three concentrations increased the LDH activity by around 0.3-fold to 0.5-fold as seen in
Figure 3.2. The LDH release in cells treated with 1 and 2 µM DOX were almost the same and
5 µM DOX showed a slightly higher increase in the enzyme activity compared to the lower
concentrations.
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Figure 3.2: DOX treatment increased the LDH release in H9c2 cells. H9c2 cells were
treated with DOX at concentrations of 1, 2 and 5 µM for 24 hours or left untreated. LDH
release was measured. One-way ANOVA analysis followed by Dunnett’s test was used to
compare groups (n= 3 independent experiments) (*P<0.05 versus control)
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3.3 DOX treatment increases caspase-3 activity in H9c2 cells
Caspase-3 activation could lead to breakdown of myofibrillar proteins and contractile
dysfunction even before cell death in cardiomyocytes (126). H9c2 cells were seeded in 24well plates at a density of 1 x 105 cells per well and incubated for 24 hours. The culture media
was replaced with DOX containing culture media at concentrations of 1 and 2 µM and
incubated further for 24 hours. Control cells were left untreated. Caspase -3 activity was
assessed in the cells. DOX treatment at 1 and 2 µM increased the caspase-3 activity in H9c2
cells by more than 6-fold and 7.5-fold, respectively (Figure 3.3).
Since the moderate injury for H9c2 cells was with 1μM DOX, when cell viability
declined about 50% and caspase 3 activity and LDH release significantly increased, this dose
was used to treat H9c2 cells in the subsequent experiments to generate the in vitro
doxorubicin-induced toxicity model. Further, DOX treatment at 1 µM for 24 hours has been
shown to induce autophagic impairment in cardiomyocytes resulting in the accumulation of
ubiquitinated proteins as well (127).
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Figure 3.3: DOX treatment increased the caspase-3 activity in H9c2 cells. H9c2 cells
were incubated with DOX at concentrations of 1 and 2 µM for 24 hours. Control cells were
left untreated. One-way ANOVA analysis followed by Dunnett’s post hoc test was used to
compare groups (n=3 independent experiments) (*P<0.05 versus control)
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3.31 DOX induces morphological alterations in H9c2 cells
Normal H9c2 cells are spindle-to stellate-shaped and can be mono- or multi-nucleated
(128). H9c2 cells were incubated with 1 µM DOX for 24 hours and the morphological
changes were examined. Changes in the structure of H9c2 cells were observed along with
cytoplasm vacuolation (Figure 3.4).

Control

DOX (1 µM)

Figure 3.31: DOX induces morphological alteration in H9c2 cells. H9C2 cells were
treated with 1 µM DOX for 24 hours. The morphological changes were examined.
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3.4 DOX treatment prevents lysosomal acidification in H9c2
cells
Efficient lysosomal functioning is enabled with the support of over 60 hydrolytic
enzymes within the organelle. These enzymes require an acidic pH of 4.5-5 for the enzymatic
breakdown of the cellular debris within the lysosomes. The proton pump V-ATPase pumps
H+ ions into the lysosomal lumen and maintains the pH within the organelle. Lysosomal
abnormalities involving dysfunctional hydrolytic enzymes have been implicated in multiple
cardiovascular disorders (51). H9c2 cells were incubated with 1 µM DOX and 100 nM
Bafilomycin A (BafA) for 24 hours. The control cells were untreated. The changes in
lysosomal pH were measured using LysoSensor yellow/blue DND-160 (Invitrogen). This
ratiometric dye has dual excitation and emission characteristics and this property was
exploited for investigating the lysosomal pH as described in the methods section.
Bafilomycin A was employed as a positive control for the experiment. It is a potent VATPase inhibitor and impairs autophagy by preventing lysosomal acidification. DOX altered
the lysosomal pH of H9c2 cells compared to the control (Figure 3.4). The changes in
lysosomal pH in response to DOX treatment were similar to the changes in Bafilomycin A
treated cells.
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Figure 3.4: DOX treatment altered the lysosomal pH by preventing acidification in
H9c2 cells. H9c2 cells were treated with DOX (1 µM) and Bafilomycin A (BAF) (100 nM)
for 24 hours. Control cells were left untreated. The lysosomal pH was determined based on
460/535 ratio. One-way ANOVA analysis followed by Tukey post hoc test was used to
compare groups (n= 10) (*P<0.05 versus control; ns-not significant)
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3.5 NAD+ and its precursor NMN prevents DOX-induced
toxicity in H9c2 cells
Declined NAD+ levels are observed in the heart of rodent models of dilated
cardiomyopathy in which NAD+ precursor supplementation improves cardiac function by
stabilizing the myocardial NAD+ levels (129). Systemic NMN administration has been
reported to up-regulate the NAD+ levels in the pancreas, heart, skeletal muscle and liver of
rodents under pathological conditions (92). DOX treatment reduces the NAD+ content in
cardiomyocytes. Previous work from our lab has also shown that pre-incubation with NAD+
precursors enhances the NAD+ levels in DOX-treated cardiomyocytes (117). Based on our
experiments in the lab and literature review, 1mM concentration of NMN and NAD+ was
used for assessing the protection imparted by these drugs in the in vitro model of DOXinduced cardiotoxicity (130).

3.5.1 NMN and NAD+ prevents DOX-induced increases in LDH
release
H9c2 cells were per-incubated with NMN/NAD+ (1 mM) for 24 hours prior to DOX
(1 µM) treatment. Cells were also treated with NMN/NAD+ alone and control cells were
untreated. LDH release was examined in the cells as it is a major index of cell injury. NMN
and NAD+ pre-incubation prevented DOX-induced increases in LDH release by nearly 0.4fold and 0.5-fold, respectively. NMN and NAD+ alone did not show much effect on H9c2
cells compared to the control (Figure 3.5a and 3.5b).
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Figure 3.5: LDH release in (a) DOX, NMN and NMN-DOX treated and (b) DOX, NAD
and NAD-DOX treated H9c2 cells. One-way ANOVA analysis followed by Tukey post hoc
test was used to compare groups (*P<0.05 versus control; **P<0.05 versus DOX)
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3.5.2 NMN and NAD+ prevents DOX-induced increase in
caspase-3 activity
It has been observed that DOX treatment increases the caspase-3 activity in H9c2
cells. Here, caspase-3 activity was measured in H9c2 cells treated with NMN or NAD+ prior
to DOX treatment. Compared to the DOX-treated group, NMN/NAD+ pre-incubation prior to
DOX, significantly reduced the caspase-3 activity (Figure 3.6 and 3.7).

*

**

Figure 3.6: NMN prevents DOX-induced increases in caspase-3 activity in H9c2 cells.
Caspase -3 activity in DOX, NMN and NMN-DOX treated H9c2 cells. One-way ANOVA
analysis followed by Tukey post hoc test was used to compare groups (n=5) (*P<0.05 versus
control; **P<0.05 versus DOX)
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Figure 3.7: NAD+ prevents DOX-induced increases in caspase-3 activity in H9c2 cells.
Caspase-3 activity in DOX, NAD and NAD-DOX treated H9c2 cells. One-way ANOVA
analysis followed by Tukey post hoc test was used to compare groups (n=5) (*P<0.05 versus
control; **P<0.05 versus DOX).
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3.5.3 NMN and NAD+ increases the viability of DOX-treated
H9c2 cells
NAD+ enhancement attenuated DOX-induced decrease in cell viability. There was
nearly 50-80% increase in the number of viable cells after NMN/NAD+ pre-incubation prior
to DOX treatment compared to the cells treated with DOX alone (Figure 3.8 and 3.9).
Upregulating NAD+ levels in H9c2 cells improved the cell viability and decreased LDH
release and caspase-3 activity, thereby protecting the cells from the deleterious effects of
DOX. Supplementing NAD+ in H9c2 cells is therefore a good strategy to replenish the DOX
depleted cellular pools and protect cells from toxicity.

**

*

Figure 3.8: NMN increased viability of DOX-treated H9c2 cells. Cell viability was
assessed in H9c2 cells treated with DOX and NMN-DOX. Control cells were untreated. Oneway ANOVA analysis followed by Tukey post hoc test was used to compare groups (n= 3)
(*P<0.05 versus control; **P<0.05 versus DOX)
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Figure 3.9: NAD+ increased viability of DOX-treated H9c2 cells. Cell viability was
assessed in H9c2 cells treated with DOX and NAD-DOX. Control cells were untreated. Oneway ANOVA analysis followed by Tukey post hoc test was used to compare groups (n= 3
independent experiments) (*P<0.05 versus control; **P<0.05 versus DOX)
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3.6 NMN and NAD+ prevents DOX-induced changes in
lysosomal pH
Since DOX also altered to the lysosomal pH of H9c2 cells apart from being toxic,
NAD+ upregulation in preventing the pH increase was examined. The pH changes were
measured using the LysoSensor probe described earlier. Both NMN and NAD+ treatment
prior to DOX incubation prevented the pH alterations (Figure 3.10 and 3.11). Statistically, pH
of the NMN/NAD+ pre-incubated cells did not differ significantly from the control cells.

**

*

Figure 3.10: NMN prevented DOX-induced pH changes. H9c2 cells pre-treated with
NMN (1 mM) for 24 hours prior to DOX treatment (1 µM) (24 hours). Control cells were left
untreated. The lysosomal pH was determined based on 460/535 ratio. One-way ANOVA
analysis followed by Tukey post hoc test was used to compare multiple groups (n= 10)
(*P<0.05 versus control; **P<0.05 versus DOX)
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Figure 3.11: NAD+ prevented DOX-induced pH changes. H9c2 cells pre-treated with
NAD+ (1 mM) for 24 hours prior to DOX treatment (1 µM) (24 hours). Control cells were
left untreated. One-way ANOVA analysis followed by Tukey post hoc test was used to
compare multiple groups (n= 10) (*P<0.05 versus control; **P<0.05 versus DOX).
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3.7 V-ATPase inhibitor, Bafilomycin A prevents NMN/NAD+
imparted protection against DOX cardiotoxicity
The V-ATPase inhibitor, Bafilomycin A, was used as a pharmacological tool to
confirm the role of V-ATPase pump in DOX cardiotoxicity. Both BAF and DOX had been
toxic to H9c2 cells and had induced pH alterations. DOX has already been reported to
prevent the autophagic flux in cardiomyocytes by preventing acidification of lysosomes (52)
and it had to be confirmed in the in vitro model used for this study as well.

3.7.1 Bafilomycin A prevents NMN/NAD+ induced decreases in
LDH release in DOX-treated H9c2 cells
H9c2 cells were pre-incubated with NMN/NAD+ (1 mM) for 24 hours and then treated
with DOX (1 µM) and BAF (1 nM) for another 24 hours. LDH release was measured in the
cells as described earlier. BAF treatment further increased the LDH release in H9c2 cells
when compared to cells treated with DOX alone. The protective effect of NMN and NAD+
were abolished by the V-ATPase inhibitor (Figure 3.12 and 3.13).
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Figure 3.12: Bafilomycin A prevented NMN induced decreases in LDH release in DOXtreated H9c2 cells. LDH release in DOX, NMN, NMN-DOX, NMN-DOX-BAF treated
H9c2 cells. One-way ANOVA analysis followed by Tukey post hoc test was used to compare
groups (n=6) (*P<0.05 versus control; **P<0.05 versus DOX; ***P<0.05 versus NMNDOX)
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Figure 3.13: Bafilomycin A prevented NAD+ induced decreases in LDH release in DOXtreated H9c2 cells. LDH release in DOX, NAD, NAD-DOX and NAD-DOX-BAF treated
H9c2 cells. One-way ANOVA analysis followed by Tukey post hoc test was used to compare
groups (n=6) (*P<0.05 versus control; **P<0.05 versus DOX; ***P<0.05 versus NMNDOX)
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3.7.2 Bafilomycin A prevents NMN/NAD+ induced protection
against alterations in lysosomal pH in DOX-treated H9c2 cells
Whether NAD+ imparted protection against lysosomal pH changes was via the V-ATPase
pump related acidification was to be determined. H9c2 cells were pre-treated with
NMN/NAD+ and then subjected to incubation with DOX (1 µM) and BAF (1 nM) for 24
hours. BAF indeed prevented the protective effect of NMN and NAD+ in maintaining
lysosomal pH (Figure 3.14 and 3.15). These results advocate that the protective mechanism
of NAD+ could be by preventing the DOX-induced modifications of the lysosomal VATPase pump.

**

*

***

Figure 3.14: Bafilomycin A prevented NMN imparted protection against DOX-induced
lysosomal pH alterations. H9c2 cells pre-treated with NMN (1 mM) for 24 hours prior to
DOX, DOX/BAF treatment (24 hours). Control cells were left untreated. Control cells were
left untreated. The lysosomal pH was determined based on 460/535 ratio. One-way ANOVA
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analysis followed by Tukey post hoc test was used to compare groups (n= 10) (*P<0.05
versus control; **P<0.05 versus DOX; ***P<0.05 versus NMN-DOX)

**

*
***

Figure 3.15: Bafilomycin A prevented NAD+ imparted protection against DOX-induced
lysosomal pH alterations. H9c2 cells pre-treated with NAD+ (1 mM) for 24 hours prior to
DOX, DOX/BAF treatment (24 hours). Control cells were left untreated. The lysosomal pH
was determined based on 460/535 ratio. One-way ANOVA analysis followed by Tukey post
hoc test was used to compare groups (n= 10) (*P<0.05 versus control; **P<0.05 versus
DOX; ***P<0.05 versus NAD-DOX)
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3.8 NMN prevents hyperacetylation of ATP6V0d1 in DOXtreated neonatal cardiomyocytes
Previous research from our lab had documented hyperacetylation of the d subunit of V0
domain (ATP6V0d1) of the V-ATPase pump in response to DOX treatment in mouse models
of DOX cardiotoxicity and neonatal cardiomyocytes. The protective effect of the NAD+
precursor, NMN in preventing hyperacetylation was hence worth investigating. This could be
one of the mechanisms by which NAD+ upregulation protects cardiomyocytes against
autophagic dysregulation by DOX. Neonatal cardiomyocytes were treated with NMN (1 mM)
for 24 hours and then incubated with DOX (1 µM) for another 24 hours. Acetylated proteins
were co-immunoprecipitated with anti-acetyl lysine antibody and separated on SDS-Page gel.
After transferring on to PVDF membrane, the proteins were probed with anti-ATP6V0D1
antibody to identify the acetylation levels on the cells. Coinciding with our earlier findings,
DOX treatment induced hyperacetylation of ATP6V0d1. NMN treatment at 1 mM
concentration for 24 hours prior to DOX incubation treatment prevented the hyperacetylation
of ATP6V0d1 (Figure 3.16).
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Figure 3.16: NMN prevented DOX-induced hyperacetylation of ATP6V0d1.
(a) (Representative image) Neonatal cardiomyocytes were incubated with NMN prior to
incubation with or without DOX. Control cells were left untreated. Co-immunoprecipitation
of acetylated proteins followed by western blot analysis of ATP6V0d1 was done. (b)
Quantification of proteins levels of acetylated ATP6V0d1 relative to ATP6V0d1. One-way
ANOVA analysis followed by Tukey post hoc test was used to compare groups (n=3)
(*P<0.05 versus CONTROL; **P<0.05 versus DOX)
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Chapter 4
4 Discussion, Limitations and Future Directions
4.1 Discussion
Cancer is a growing burden on the Canadian health sector and the leading cause of
death in the country. Several measures have been undertaken by the Government of Canada
in addressing this issue and around $159 million have been invested in cancer research in the
country in 2009-10 alone through the Canadian Institute of Cancer Research (131). The
government has also invested $250 million to improve the quality of lives of Canadian
Cancer patients and survivors through its initiative, Canadian Partnership Against Cancer, an
independent not-for-profit organization. Despite of all these measures, nearly half of all
Canadians are expected to develop cancer in their lifetime.
Doxorubicin has been a frontline drug in the treatment of cancer since decades and
hence is a major player in the pharmaceutical industry in terms of revenue too. The major
concern of this drug is its toxic effect on the heart posing acute and chronic threats. Though
Doxorubicin cardiotoxicity has been widely studied, an effective treatment option is yet to be
achieved. Cardiac toxicity associated with DOX administration is dependent on risk factors
such as cumulative and age. Antioxidant supplementation along with DOX have so far been
limited in preventing cardiotoxicity in the clinical scenario (132). Clinical studies on the
effectiveness of beta-blockers like carvedilol, Angiotensin II receptor blockers (ARB) and
Angiotensin converting enzyme (ACE) inhibitors, in preventing doxorubicin cardiotoxicity
have resulted in mixed or no desired outcomes (133). Dexrazoxane, a bis-dioxopiperazine
compound is co-administered with Doxorubicin to prevent cardiotoxic occurrences, but
reduced chemotherapeutic efficacy and side effects like myelosuppression have been reported
in patients (134). Effective treatment strategies in managing the toxic effects of DOX would
open more room to exploit the therapeutic potential of the drug.
The role of autophagy in DOX cardiotoxicity has gained considerable interest in
recent years. Stimulating basal autophagy by calorific restriction and mTORC inhibition has
been demonstrated to reduce DOX toxicity in rodents. Also, interfering with the proteins
involved in late autophagic machinery has been reviewed as a promising strategy and could
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contribute in alleviating the complication (135). This study focuses on revealing the
mechanisms of impaired lysosome acidification in cardiomyocytes causing autophagic
disruption in response to doxorubicin treatment. A novel role of NAD+ precursor, NMN, in
establishing the basal autophagic machinery in DOX treated cardiomyocytes by augmenting
impaired lysosome acidification been proposed. This study establishes the defects induced by
Doxorubicin on the lysosomal V-ATPase, the proton pump essential for regulating pH.
Further, the therapeutic scope and mechanism of NMN, the NAD+ precursor in preventing
Doxorubicin-induced autophagic dysregulation by establishing the lysosomal function has
been evaluated.

4.1.1 Doxorubicin induces toxicity and death in cardiomyocytes
In the clinical scenario, DOX induces cardiomyocyte death within hours of
intravenous administration (136). Dose-dependent toxicity cardiotoxic effects of DOX have
been established in this study on the rat myoblast cell line H9c2 and on human induced
pluripotent stem cells-derived cardiomyocytes and adult cardiomyocytes by researchers
elsewhere. Increases in the LDH release, DNA fragmentation and activation of caspases are
observed in these cells (137,138).
Increased LDH activity is evident in human hearts with defects and end-stage failure
and early interventions have been reported to improve the clinical outcomes of these patients.
LDH is a sensitive method and an early biochemical indicator of myocardial complications.
Plasma levels of LDH increase within 8-12 hours of cardiac injury, peaks in 2-3 days and
remains elevated for 7-10 days. High serum LDH levels predicts short survival time in
patients with multiple myeloma treated with a combinatorial Doxorubicin drug regimen
(139–142). DNA fragmentation is a marker of apoptosis and increased levels of fragmented
DNA are observed in cardiomyopathy which often transitions to heart failure. Oxidative
stress induces high levels of DNA damage in patients with cardiovascular diseases (143,144).
Caspases are cysteinyl aspartate specific proteases involved in the cleavage of several
proteins propagating cellular homeostasis by inducing apoptosis, proliferation, and
inflammation. These proteases are widely expressed, and 12 human caspases have been
identified till date. Tightly regulated activation of caspases prevents premature cell death.
Activation of caspases in the heart degrades the myofibrillar proteins such as actin and actinin
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resulting in the impairment of the myofibrillar ATPase active and contractile dysfunction. In
normal conditions, due to their limited proliferative capacity, only around 0.001-0.01% of
cardiomyocytes undergo apoptosis. Caspase-3 is an executioner caspase directly cleaving the
substrate proteins and promotes the downstream cascade of events in apoptosis. Caspase
activation degrades autophagic proteins like Beclin-1, Atg5 and Atg7, impairing the
autophagic machinery and converts pro-autophagic proteins to pro-apoptotic proteins, thereby
triggering apoptosis (145). The myocardial cells exhibit a stage of interrupted apoptosis,
where there is contractile dysfunction with increased caspase-3 activity but normal nuclei.
This prolonged pre-death stage suggests that cells have the possibility to be rescued with
restoration of myocardial function. (126,146–148).
Increased caspase-3 expression is found in the hearts with end-stage heart failure and
ventricular arrythmias and considerable reduction of this protease is seen in patients with left
ventricular assisted device (LVAD) support. Over-expressing cardiac specific caspase-3 in
mice induced myofibrillar ultrastructural damages and lethality was also reported in caspase3 transgenic mice with increased infarct size when subjected to myocardial ischemiareperfusion injury (148). DOX treatment induces apoptosis in cardiomyocytes and rat cardiac
ventricles by activating caspase-3 (149). In consistence with data published by peers, the
present study also reports a dose-dependent increase in caspase-3 activity of H9c2 cells in an
in vitro model of DOX cardiotoxicity. Although the exact mechanism of caspase-3 activation
by DOX remains unclear, H2O2 induced ROS is predominantly considered as the mediator of
caspase-3 activation in cardiomyocytes in contrast to caspase-3 activation mediated by p53 in
tumour cells (150).

4.1.2 Doxorubicin inhibits acidification and induces lysosomal
dysfunction in cardiomyocytes
With high rates of oxygen consumption and aerobic respiration, the post-mitotic
myocardial cells are highly susceptible to damage associated with pathological conditions
such as aging and disease. Due to the lack of proliferative and renewal capacities, myocardial
cells depend extensively on the intracellular recycling mechanisms for their survival.
Lysosomes, being the key organelles demonstrating degradative and salvaging capabilities,
are vital in preserving the viability of these cells. Autophagic clearance of damaged and
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defective proteins and organelles in the cell carried out by lysosomes maintains
cardiomyocyte homeostasis and longevity. Cells when subjected to stress, activate autophagy
to get rid of the malfunctional cellular structures formed in response to various stimuli.
Insufficient autophagy in stressed cells could result in the accumulation of ROS and
induction of apoptosis. In cardiomyocytes, proper lysosomal function and autophagy is of
utmost importance as the respiratory organelle mitochondria is actively functioning and often
suffers from oxidative damage and should be recycled (50). Autophagic flux impairment has
been implicated in doxorubicin cardiotoxicity and our lab has reported this previously.
Increased steady-state LC3-II levels indicates activation of autophagic flux or downstream
blockage of autophagic vacuole processing. Bafilomycin A, the inhibitor of late stage
autophagy, increased the LC3-II protein levels in saline-treated cardiomyocytes. Compared to
the saline-treated cells, Bafilomycin A treatment did not further increase the LC3-II protein
levels in doxorubicin-treated cardiomyocytes suggesting a block in the autophagic flux (117).
The hydrolytic enzymes within the lysosomes are tightly regulated by the pH within
the organelle. An acidic pH of 4.5-5 is essential for the enzymatic activity in the interior of
lysosomes. The interior perimeter of the lysosome is protected from the attack from its own
enzymes with the help of a glycocalyx lining. The pH gradient is generated and maintained
with the help of protons pumped into the lysosomal lumen by the V-ATPase pump. ATP
hydrolysis at the cytoplasmic V1 domain of V-ATPase imports protons via the membraneembedded V0 domain. The pumping mechanism is tightly regulated by the reversible
assembly of the domains and has been described in detail in the first chapter. Disorders in
lysosomal acidification have been implicated in several neurogenerative diseases, Crohn’s
disease and lipotoxicity (151–153). Doxorubicin treatment inhibited the lysosomal
acidification in neonatal rat ventricular myocytes resulting in the disruption of autophagic
flux and accumulation of ROS (52), leading to cell death.
Using the V-ATPase inhibitor Bafilomycin A as a positive control, the lysosomal
acidification defects in DOX-treated H9c2 cells have been established in this study.
Compared to the control group, H9c2 cells incubated with Bafilomycin A and Doxorubicin
showed similar alterations in lysosomal pH. The results obtained indicate that Doxorubicin
inhibits V-ATPase, prevents the acidification of lysosomes, and impairs the autophagic
machinery in cardiomyocytes. Since Bafilomycin A impaired V-ATPase activity partly by
inhibiting the subunit c of V0 domain, DOX mediated inhibition of V-ATPase subunits was
worth investigating. Preliminary results from an ongoing research in our laboratory have
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indeed identified DOX mediated modification on the subunit d of the V-ATPase V0 domain.
Interestingly, none of the other subunits from the V1 or V0 domains showed any alterations.

4.1.3 NMN confers protection against Doxorubicin-induced
toxicity and death in cardiomyocytes
NAD+ homeostasis in the cell is vital for regulating cellular bioenergetics as it is an
important co-factor for many intracellular enzymatic reactions. Altered NAD+ homeostasis
and depleted levels of NAD+ have been linked to aging and development of several diseases
of the brain, heart, liver, skeletal muscle, kidney, and gut. Decreased levels of NAD+ have
been linked to multiple cardiac pathologies. Overactivation of the NAD+ consuming
enzymes in the heart leads to the depletion of the cofactor and affects the normal functioning
of the cells in the organ. In cardiomyocytes too, as in other cells, NAD+ is critical for the
maintaining the fuel oxidation. NAD+ gets reduced to NADH, which get re-oxidised in the
mitochondria to produce ATP in a process termed as oxidative phosphorylation. This process
generates about 95 % of the cardiac ATP content. The phosphorylated NAD+, NADP+, is an
essential component in the pentose phosphate pathway generating NADPH and ribose 5phosphate. NADPH is involved in lipid biosynthesis and protects against ROS. In models of
cardiac dysfunction, NAD+ supplementation using precursors re-establishes the depleted
NAD+ pools and normalized the redox reactions in the cell (94,154).
The NAD+ precursor, NMN, have shown promising therapeutic effects on various
cardiovascular complications. NMN prevented ischemic injury and increased sirtuin activity
and vasodilatory function in rodent models of heart ischemia/reperfusion. This NAD+
precursor also showed potential to reverse left ventricular contractile dysfunction in animal
models (94). Our lab has recently reported the protective effect of another NAD+ precursor,
NR in ameliorating Doxorubicin-induced cardiotoxicity in mice via modulating the
NAD+/SIRT1 pathway (117). This study for the first time demonstrates the potential of
NMN in preventing toxic effects of Doxorubicin in an in vitro cell culture model. Both
NAD+ and NMN improved the viability of H9c2 cells and prevented the increases in LDH
release and caspase-3 activity. Based on the results from this study, NMN attenuated the cell
damage in Doxorubicin treated cells and prevented cell death.
Orally administered NMN is rapidly absorbed and converted to NAD+ in peripheral
organs and is retained longer in the body than other NAD+ intermediates (101). A clinical
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trial to investigate the safety profile of NMN revealed no side effects up to single oral doses
of 0.5 gram/day in healthy men. NMN was effectively metabolised and did not cause any
adverse clinical symptoms in the subjects. The biochemical analysis revealed normal ranges
of serum creatinine, chloride, and blood glucose levels (155). Another clinical trial to
investigate the effects of NMN on cardiometabolic functions are currently underway and is
expected to be completed soon (156). Bioavailability and therapeutic value of NMN can
hence be exploited and has the potential to be translated in mitigating Doxorubicin
cardiotoxicity.

4.1.4 NMN protects cardiomyocytes from Doxorubicin-induced
alterations in lysosomal pH
As mentioned earlier, efficient lysosome functioning is critical in post-mitotic cells
like cardiomyocytes. Insufficient autophagy in cardiomyocytes lead to the accumulation of
defective organelles like mitochondria and damaged proteins in cell and contributes to the
ROS generation leading to oxidative stress. Lysosomal acidification by V-ATPase is vital in
maintaining autophagic flux. NR supplementation prevented lysosomal alkalinization in
Doxorubicin- treated adult cardiomyocytes (117). The current study also validated the effects
of NAD+ supplementation in preventing pH increases in cardiomyocytes in response to DOX
treatment. Treatment with NMN blocked the effects of Doxorubicin on the lysosomal pH of
H9c2 cells. NAD+ treatment also showed similar results suggesting the NMN mediated
lysosomal pH preservation could be facilitated by the conservation of the NAD+ pool in
H9c2 cells. Since lysosomal pH is maintained by V-ATPase activity, it is possible that NAD+
may veil the proton pump from the deleterious effects of Doxorubicin. Hence, we postulated
that the hyperacetylation of the V-ATPase V0d subunit induced by Doxorubicin identified in
our laboratory, could be prevented by NMN.

4.1.5 Bafilomycin A abrogates the protective effects of NMN in
Doxorubicin-induced cardiotoxicity
Doxorubicin inhibits lysosomal acidification in cardiomyocytes by inhibiting VATPase and blocking proton transport (52). To clarify the role of V-ATPases in Doxorubicin
mediated cardiotoxicity, Bafilomycin A, a specific V-ATPase inhibitor, was used to inhibit
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the proton transport mechanism in H9c2 cells. NAD+ upregulation was unable to rescue the
cells from lysosomal pH increases, when Bafilomycin A was incubated with Doxorubicin.
The protection imparted by NMN in preventing lysosomal pH alterations in H9c2 cells were
hence abrogated suggesting a modulatory role of NAD+ on the V-ATPase pump activity.
Bafilomycin A inhibits lysosomal acidification by binding to the c subunit of the VATPase V0 domain and as mentioned earlier, we have preliminary results from our lab
validating a similar modus operandi of Doxorubicin on the proton pump. Since NAD+ and
NMN failed to protect the lysosomal pH of DOX-treated H9c2 cells in the presence of the VATPase inhibitor, it was anticipated that NAD+ upregulation might be exerting its effects via
modulating V-ATPase.

4.1.6 NMN prevents hyperacetylation of the d subunit of VATPase pump V0 domain
NMN supplementation restores the NAD+ levels and stimulates the activity of the
NAD+ dependent lysine deacetylase SIRT1 in the heart. SIRT1 inhibitor splitomycin
prevented the protective effects of NMN in heart ischemia-reperfusion injury justifying the
role of SIRT1 pathway in NAD+ mediated cardio protection (130). Hyperacetylation of
various autophagy related proteins and transcription factors including TFEB have been
implicated in several cardiovascular complications. Activation of DNA repair enzymes like
PARPs deplete the NAD+ reserves in the cells and constrain the deacetylation activity of
sirtuins. Under normal physiological conditions, PARPs are also deacetylated and inhibited
by sirtuins to preserve the NAD+ levels in cardiomyocytes. But damages to the DNA leads to
NAD+ consumption due to PARP activation and inhibition of sirtuin activity (157).
Doxorubicin induced epigenetic modifications such as DNA methylation and histone
modifications exacerbate the toxic effects of the drug on cardiomyocytes by altering the gene
expression (158). Our lab has previously reported robust increase in p53 acetylation in
cardiomyocytes treated with Doxorubicin. NAD+ supplementation prevented the acetylation,
but this protective effect was abolished when the cells were co-incubated with the SIRT1
inhibitor, EX-527, highlighting the role of NAD+ mediated deacetylation as a defensive
phenomenon in Doxorubicin cardiotoxicity (117).
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In line with the ongoing research in our laboratory on DOX-induced cardiotoxicity,
this study explored the potential of NMN assisted deacetylation mechanism on the DOXinduced hyperacetylation on the V-ATPase V0d1 subunit. Pre-incubating neonatal
cardiomyocytes with NMN prevented hyperacetylation as evidenced by coimmunoprecipitation and western blotting experiments. Thus, a unique role of the NAD+
precursor, NMN, was established in this study which could open doors for further meritorious
investigations. Preventing the hyperacetylation of the V-ATPase d1 subunit is assumed to be
a possible mechanism of NMN mediated inhibition of lysosomal pH increases in Doxorubicin
treated cells.
The V-ATPase d subunit is ubiquitously expressed and links the proteolipid c ring of
V0 and the central stalk of V1 (55). Subunit d is also hydrophilic and is located on the
cytoplasmic side of the c ring. Binding sites for the D and F subunits of the V1 domain are
present on subunit d and it is a vital protein of the V-ATPase rotary complex comprising of
D, F and proteolipid ring (159). Unless complexed with the V0 domain, d doesn’t bind to the
D subunit of central stalk (60). During disassembly of the V-ATPase domains, subunit a
separates from the V1 subunit and binds to d, preventing its rotation (58). Crystal structure
and electron microscopic analysis suggests that the d subunit serves as a socket to attach
central stalk subunits of V1 onto the V0 phospholipid ring, coupling the two domains (160).
Subunit d dissociates from the membrane on treating with alkaline reagents such as Na2CO3
or 5M urea and at a pH of 11.5 in in vitro experiments. Moreover, subunit d is the only
component of V0 that is not an integral membrane protein (63). Based on all these literatures,
it is logical to assume that subunit d is prone to acetylation modifications when cells are
subjected to Doxorubicin treatment either directly by DOX/ROS or indirectly by
NAD+/SIRT inhibition.

4.2 Concluding Remarks
This study uncovers a novel role of NMN in establishing the basal autophagic
machinery in DOX treated cardiomyocytes by improving impaired lysosome acidification.
The d subunit of V-ATPase V0 sector is the only protein in the membranous domain of the
proton pump to be localised to the periphery of the lysosomal membrane and could be prone
to modifications by DOX directly or indirectly. It is an important regulator of proton
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transport and hence hyperacetylation could account for DOX-induced lysosomal dysfunction
in cardiomyocytes. Pre-incubation with the NAD+ precursor, NMN, averted hyperacetylation
of the V-ATPase d subunit in DOX-treated cardiomyocytes. Also, NMN and NAD+ imparted
protection to H9c2 cardiomyocyte cells from Doxorubicin toxicity by preventing cell injury
and lysosomal pH alterations (Figure 4.1). Based on these findings and the safety profile of
NMN, this molecule could be credibly considered as a beneficial drug in ameliorating
Doxorubicin cardiotoxicity.

A

B

Figure 4.1: Schematic illustration of the study. (A) Doxorubicin depletes the NAD+
content and stimulates hyperacetylation of ATP6V0d1 thereby preventing lysosomal
acidification and inducing cardiomyocyte cell toxicity. (B) NAD+ precursor, NMN,
supplements the NAD+ pools depleted by Doxorubicin and prevents the hyperacetylation of
ATP6V0d1 and hence maintains acidic lysosomal pH and prevents cardiomyocyte cell
toxicity.
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4.3 Limitations
1) Direct evidence of NAD+ upregulation by NMN in H9c2 cells has not been
included in this study. However, this has been reported by multiple researchers and our lab
also has unpublished data of NAD+ upregulation by NMN in H9c2 cells.
2) This study has focussed on therapeutic scope of NMN in in vitro models of
Doxorubicin cardiotoxicity. Though NMN has shown cardioprotective effects in in vivo
models of cardiac complications and NR has shown potential in rodent models of
Doxorubicin cardiotoxicity, additional studies are required for validating the protective
effects of NMN in Doxorubicin cardiotoxicity.
3) Though pharmacological inhibitors such as Bafilomycin A, serves the purpose in
providing mechanistic evidence of V-ATPase inhibition, genetic manipulations would have
supported the claim further.
4) NMN indeed did prevent hyperacetylation of ATP6V0d1 and inhibited lysosomal
pH increases in Doxorubicin treated cardiomyocytes, but other mechanisms of protection on
lysosomal functioning and autophagic flux in Doxorubicin cardiotoxicity may exist which
warrants further investigations.
5) Inclusion of in vitro lysosomal imaging techniques would have aided the intention
of this study and would have spiked the visual interest of readers as well.

4.4 Future Directions
NAD+ mediated protection in Doxorubicin cardiotoxicity is speculated to include the
sirtuin pathway. Though our lab has reported the involvement of SIRT1 in the protective
mechanism of NR in Doxorubicin cardiotoxicity using pharmacological inhibitors (117), we
intent to further verify this, in the mechanism of protection imparted by NMN as well.
Pharmacological interventions and genetic manipulations will be used to elucidate the role of
sirtuins, particularly SIRT1, using in vitro and in vivo models of disease.
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Negative regulation of TFEB, the master regulator of lysosome biogenesis has been
implicated in the progression of Doxorubicin cardiotoxicity (161). Acetylation of TFEB
prevents its activation and stalls the synthesis of several proteins in the autophagic machinery
(99). The role of NAD+ upregulation in augmenting TFEB function and lysosome biogenesis
will be evaluated in future experiments.
The acetylation patterns on ATP6V0d1 in response to Doxorubicin treatment will be
investigated using mass spectrophotometry. Individual site mutations will be generated at the
identified acetylation sites through gene mutagenesis and the vital acetylation sites impacting
the efficient functioning of V-ATPase will be explored. Using genetic manipulations, the role
of ATP6V0d1 will be studied in in vivo models of Doxorubicin cardiotoxicity as well.
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